

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the Query Builder analysis.

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview

Query Builder Report: This report details the results of an analysis generated by the Sentinel Query Builder application. Query Builder enables FDA to visualize, draft, and create standardized medical product utilization queries examining dispensing patterns and cohort characteristics using a set of pre-defined parameters. This is a Type 5 (Medical Product Utilization) analysis as described in the Query Request Package (QRP) documentation.

Request Description: In this request, we investigated utilization patterns of drugs with approved REMS (Risk Evaluation and Mitigation Strategies) that employ ETASU (Elements to Assure Safe Use). This is report 2 of 2. Products assessed in this report include: alvimopan, testosterone undecanoate, panobinostat, teduglutide, alosetron, denosumab, vigabatrin, idelalisib, romiplostim, and olanzapine extended release. Report 1 assessed 10 additional products.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 10.1.1

Data Source: We executed this request on IBM® MarketScan® Commercial Claims and Encounters Database and Medicare Supplemental Database, which included 149 million members on October 15, 2021. The study period included data from January 1, 2010 to September 30, 2020. Please see Appendix A for data availability dates.

Limitations: Algorithms used to define exposures and inclusion and exclusion criteria are imperfect; thus it is possible that there may be misclassification. Therefore, data should be interpreted with these limitations in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel Query Builder, please refer to the documentation (<https://dev.sentinelssystem.org/projects/QB/repos/querybuilder/browse>).

Table of contents	
Table 1a	Baseline table (Alosetron)
Table 1b	Baseline table (Alvimopan)
Table 1c	Baseline table (Denosumab)
Table 1d	Baseline table (Idelalisib)
Table 1e	Baseline table (Olanzapine Extended Release)
Table 1f	Baseline table (Panobinostat)
Table 1g	Baseline table (Romiplostim)
Table 1h	Baseline table (Teduglutide)
Table 1i	Baseline table (Testosterone undecanoate)
Table 1j	Baseline table (Vigabatrin)
Table 2a	Distribution of cumulative exposure duration, by length categories, all episodes, in days
Table 2b	Distribution of cumulative exposure duration, by length categories, all episodes, in days, by sex
Table 2c	Distribution of cumulative exposure duration, by length categories, all episodes, in days, by age group (years)
Table 3a	Descriptive statistics of cumulative exposure duration, all episodes, in days
Table 3b	Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex
Table 3c	Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)
Table 4a	Distribution of first exposure episode duration, by length categories, in days
Table 4b	Distribution of first exposure episode duration, by length categories, in days, by sex
Table 4c	Distribution of first exposure episode duration, by length categories, in days, by age group (years)
Table 5a	Descriptive statistics of first exposure episode duration, in days
Table 5b	Descriptive statistics of first exposure episode duration, in days, by sex
Table 5c	Descriptive statistics of first exposure episode duration, in days, by age group (years)
Table 6a	Distribution of second and subsequent exposure episode duration, by length categories, in days
Table 6b	Distribution of second and subsequent exposure episode duration, by length categories, in days, by sex
Table 6c	Distribution of second and subsequent exposure episode duration, by length categories, in days, by age group (years)
Table 7a	Descriptive statistics of second and subsequent exposure episode duration, in days
Table 7b	Descriptive statistics of second and subsequent exposure episode duration, in days, by sex
Table 7c	Descriptive statistics of second and subsequent exposure episode duration, in days, by age group (years)
Table 8a	Distribution of all episode durations, by length categories, in days
Table 8b	Distribution of all episode durations, by length categories, in days, by sex
Table 8c	Distribution of all episode durations, by length categories, in days, by age group (years)
Table 9a	Descriptive statistics of all episode durations, in days
Table 9b	Descriptive statistics of all episode durations, in days, by sex
Table 9c	Descriptive statistics of all episode durations, in days, by age group (years)
Table 10a	Distribution of days supplied per dispensing, by length categories
Table 10b	Distribution of days supplied per dispensing, by length categories, by sex
Table 10c	Distribution of days supplied per dispensing, by length categories, by age group (years)
Table 11a	Descriptive statistics of days supplied per dispensing
Table 11b	Descriptive statistics of days supplied per dispensing, by sex
Table 11c	Descriptive statistics of days supplied per dispensing, by age group (years)
Table 12a	Descriptive statistics of the length of the first gap between treatment episodes, in days
Table 12b	Descriptive statistics of the length of the first gap between treatment episodes, in days, by sex
Table 12c	Descriptive statistics of the length of the first gap between treatment episodes, in days, by age group (years)
Table 13a	Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days
Table 13b	Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by sex
Table 13c	Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by age group (years)
Table 14a	Descriptive statistics of the length of all gaps between treatment episodes, in days
Table 14b	Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex
Table 14c	Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years)
Table 15	Counts of reason for censoring, all episodes and first episode
Table 16	Cohort Attrition Table

Table of contents

Appendix A	Dates of Available Data for Each Data Partner (DP) up to Request End Date (09/30/2020) as of Query Distribution Date
Appendix B	Specifications Used to Define Parameters in this Query
Appendix C	List of Generic and Brand Names of Medical Products Used to Define Exposures of Interest in this Request List of
Appendix D	Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures of Interest in this Request

Table 1a: Baseline table (Alosetron)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	5,261	
Demographics		
Mean Age (Years)	49.6	15.1
Age (Years): 00-17	30	0.6%
Age (Years): 18-24	363	6.9%
Age (Years): 25-40	1,097	20.9%
Age (Years): 41-64	3,073	58.4%
Age (Years): 65+	698	13.3%
Sex (Female)	4,614	87.7%
Sex (Male)	647	12.3%
Year (2010)	524	10.0%
Year (2011)	892	17.0%
Year (2012)	834	15.9%
Year (2013)	688	13.1%
Year (2014)	625	11.9%
Year (2015)	410	7.8%
Year (2016)	305	5.8%
Year (2017)	361	6.9%
Year (2018)	239	4.5%
Year (2019)	236	4.5%
Year (2020)	147	2.8%
Recorded history of:		
Prior combined comorbidity score ³	0.5	1.4
Acquired Hypothyroidism	699	13.3%
Acute Myocardial Infarction	7	0.1%
Alzheimer's Disease	8	0.2%
Alzheimer's Disease, Related Disorders, or Senile Dementia	28	0.5%
Anemia	518	9.8%
Asthma	423	8.0%
Atrial Fibrillation	90	1.7%
Benign Prostatic Hyperplasia	41	0.8%
Breast Cancer	86	1.6%
Cataracts	313	5.9%
Chronic Kidney Disease	263	5.0%
Chronic Obstructive Pulmonary Disease	284	5.4%
Colorectal Cancer	54	1.0%
Depression	996	18.9%
Diabetes	661	12.6%
Endometrial Cancer	16	0.3%
Glaucoma	223	4.2%
Heart Failure	81	1.5%
Hip / Pelvic Fracture	13	0.2%
Hyperlipidemia	1,222	23.2%
Hypertension	1,504	28.6%
Ischemic Heart Disease	217	4.1%
Lung Cancer	11	0.2%
Osteoporosis	160	3.0%
Prostate Cancer	7	0.1%
Rheumatoid Arthritis / Osteoarthritis	815	15.5%
Stroke / Transient Ischemic Attack	66	1.3%
Health Service Utilization Intensity:		

Table 1a: Baseline table (Alosetron)

Characteristic ¹	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	12.2	10.3
Mean number of emergency room encounters (ED)	0.4	1.2
Mean number of inpatient hospital encounters (IP)	0.1	0.5
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	2.1	4.6
Mean number of filled prescriptions	22.0	17.9
Mean number of generics	10.3	6.3
Mean number of unique drug classes	9.7	5.6

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1b: Baseline table (Alvimopan)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	7	
Demographics		
Mean Age (Years)	52.8	19.2
Age (Years): 00-17	-	-
Age (Years): 18-24	1	14.3%
Age (Years): 25-40	-	-
Age (Years): 41-64	4	57.1%
Age (Years): 65+	2	28.6%
Sex (Female)	3	42.9%
Sex (Male)	4	57.1%
Year (2010)	2	28.6%
Year (2011)	-	-
Year (2012)	1	14.3%
Year (2013)	2	28.6%
Year (2014)	-	-
Year (2015)	-	-
Year (2016)	1	14.3%
Year (2017)	-	-
Year (2018)	-	-
Year (2019)	-	-
Year (2020)	1	14.3%
Recorded history of:		
Prior combined comorbidity score ³	1.7	2.1
Acquired Hypothyroidism	0	0.0%
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	0	0.0%
Anemia	1	14.3%
Asthma	0	0.0%
Atrial Fibrillation	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Breast Cancer	0	0.0%
Cataracts	0	0.0%
Chronic Kidney Disease	0	0.0%
Chronic Obstructive Pulmonary Disease	1	14.3%
Colorectal Cancer	2	28.6%
Depression	1	14.3%
Diabetes	1	14.3%
Endometrial Cancer	0	0.0%
Glaucoma	0	0.0%
Heart Failure	0	0.0%
Hip / Pelvic Fracture	0	0.0%
Hyperlipidemia	3	42.9%
Hypertension	2	28.6%
Ischemic Heart Disease	0	0.0%
Lung Cancer	0	0.0%
Osteoporosis	0	0.0%
Prostate Cancer	1	14.3%
Rheumatoid Arthritis / Osteoarthritis	1	14.3%
Stroke / Transient Ischemic Attack	0	0.0%
Health Service Utilization Intensity:		

Table 1b: Baseline table (Alvimopan)		
Characteristic¹	N/Mean	%/Std Dev²
Mean number of ambulatory encounters (AV)	11.0	2.8
Mean number of emergency room encounters (ED)	0.7	1.1
Mean number of inpatient hospital encounters (IP)	1.0	0.6
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	2.4	4.0
Mean number of filled prescriptions	13.4	9.9
Mean number of generics	8.0	3.5
Mean number of unique drug classes	7.7	3.3

¹All metrics based on total number of unique patients
²Value represents standard deviation where no % follows the value

Table 1c: Baseline table (Denosumab)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	156,995	
Demographics		
Mean Age (Years)	67.0	11.7
Age (Years): 00-17	37	0.0%
Age (Years): 18-24	118	0.1%
Age (Years): 25-40	1,772	1.1%
Age (Years): 41-64	80,140	51.0%
Age (Years): 65+	74,928	47.7%
Sex (Female)	134,414	85.6%
Sex (Male)	22,581	14.4%
Year (2010)	393	0.3%
Year (2011)	4,084	2.6%
Year (2012)	26,278	16.7%
Year (2013)	19,695	12.5%
Year (2014)	20,635	13.1%
Year (2015)	17,515	11.2%
Year (2016)	18,747	11.9%
Year (2017)	14,914	9.5%
Year (2018)	13,999	8.9%
Year (2019)	12,921	8.2%
Year (2020)	7,814	5.0%
Recorded history of:		
Prior combined comorbidity score ³	2.0	3.0
Acquired Hypothyroidism	28,234	18.0%
Acute Myocardial Infarction	720	0.5%
Alzheimer's Disease	1,076	0.7%
Alzheimer's Disease, Related Disorders, or Senile Dementia	3,239	2.1%
Anemia	26,642	17.0%
Asthma	9,932	6.3%
Atrial Fibrillation	9,694	6.2%
Benign Prostatic Hyperplasia	4,241	2.7%
Breast Cancer	32,303	20.6%
Cataracts	24,076	15.3%
Chronic Kidney Disease	19,289	12.3%
Chronic Obstructive Pulmonary Disease	16,684	10.6%
Colorectal Cancer	2,298	1.5%
Depression	17,183	10.9%
Diabetes	21,971	14.0%
Endometrial Cancer	774	0.5%
Glaucoma	13,678	8.7%
Heart Failure	6,636	4.2%
Hip / Pelvic Fracture	3,795	2.4%
Hyperlipidemia	61,387	39.1%
Hypertension	68,860	43.9%
Ischemic Heart Disease	16,111	10.3%
Lung Cancer	6,876	4.4%
Osteoporosis	108,548	69.1%
Prostate Cancer	10,766	6.9%
Rheumatoid Arthritis / Osteoarthritis	46,230	29.4%
Stroke / Transient Ischemic Attack	4,174	2.7%
Health Service Utilization Intensity:		

Table 1c: Baseline table (Denosumab)

Characteristic ¹	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	14.7	12.3
Mean number of emergency room encounters (ED)	0.3	0.9
Mean number of inpatient hospital encounters (IP)	0.2	0.5
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	2.9	6.1
Mean number of filled prescriptions	17.1	15.0
Mean number of generics	7.7	5.4
Mean number of unique drug classes	7.2	4.9

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1d: Baseline table (Idelalisib)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	318	
Demographics		
Mean Age (Years)	66.9	11.6
Age (Years): 00-17	-	-
Age (Years): 18-24	-	-
Age (Years): 25-40	4	1.3%
Age (Years): 41-64	151	47.5%
Age (Years): 65+	163	51.3%
Sex (Female)	138	43.4%
Sex (Male)	180	56.6%
Year (2010)	-	-
Year (2011)	-	-
Year (2012)	-	-
Year (2013)	-	-
Year (2014)	72	22.6%
Year (2015)	96	30.2%
Year (2016)	68	21.4%
Year (2017)	36	11.3%
Year (2018)	20	6.3%
Year (2019)	16	5.0%
Year (2020)	10	3.1%
Recorded history of:		
Prior combined comorbidity score ³	3.3	2.8
Acquired Hypothyroidism	47	14.8%
Acute Myocardial Infarction	3	0.9%
Alzheimer's Disease	0	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	4	1.3%
Anemia	148	46.5%
Asthma	19	6.0%
Atrial Fibrillation	34	10.7%
Benign Prostatic Hyperplasia	21	6.6%
Breast Cancer	13	4.1%
Cataracts	42	13.2%
Chronic Kidney Disease	77	24.2%
Chronic Obstructive Pulmonary Disease	51	16.0%
Colorectal Cancer	3	0.9%
Depression	33	10.4%
Diabetes	63	19.8%
Endometrial Cancer	0	0.0%
Glaucoma	21	6.6%
Heart Failure	30	9.4%
Hip / Pelvic Fracture	2	0.6%
Hyperlipidemia	107	33.6%
Hypertension	145	45.6%
Ischemic Heart Disease	61	19.2%
Lung Cancer	7	2.2%
Osteoporosis	6	1.9%
Prostate Cancer	10	3.1%
Rheumatoid Arthritis / Osteoarthritis	57	17.9%
Stroke / Transient Ischemic Attack	9	2.8%
Health Service Utilization Intensity:		

Table 1d: Baseline table (Idelalisib)

Characteristic ¹	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	22.7	14.9
Mean number of emergency room encounters (ED)	0.5	1.1
Mean number of inpatient hospital encounters (IP)	0.6	1.1
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	5.5	11.0
Mean number of filled prescriptions	21.3	15.3
Mean number of generics	10.7	5.8
Mean number of unique drug classes	10.0	5.0

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1e: Baseline table (Olanzapine Extended Release)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	721	
Demographics		
Mean Age (Years)	39.5	21.1
Age (Years): 00-17	73	10.1%
Age (Years): 18-24	190	26.4%
Age (Years): 25-40	164	22.7%
Age (Years): 41-64	201	27.9%
Age (Years): 65+	93	12.9%
Sex (Female)	345	47.9%
Sex (Male)	376	52.1%
Year (2010)	4	0.6%
Year (2011)	66	9.2%
Year (2012)	73	10.1%
Year (2013)	83	11.5%
Year (2014)	86	11.9%
Year (2015)	66	9.2%
Year (2016)	90	12.5%
Year (2017)	65	9.0%
Year (2018)	69	9.6%
Year (2019)	57	7.9%
Year (2020)	62	8.6%
Recorded history of:		
Prior combined comorbidity score ³	1.8	1.9
Acquired Hypothyroidism	66	9.2%
Acute Myocardial Infarction	4	0.6%
Alzheimer's Disease	43	6.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	93	12.9%
Anemia	64	8.9%
Asthma	66	9.2%
Atrial Fibrillation	31	4.3%
Benign Prostatic Hyperplasia	12	1.7%
Breast Cancer	10	1.4%
Cataracts	25	3.5%
Chronic Kidney Disease	57	7.9%
Chronic Obstructive Pulmonary Disease	50	6.9%
Colorectal Cancer	1	0.1%
Depression	331	45.9%
Diabetes	75	10.4%
Endometrial Cancer	1	0.1%
Glaucoma	14	1.9%
Heart Failure	18	2.5%
Hip / Pelvic Fracture	4	0.6%
Hyperlipidemia	136	18.9%
Hypertension	225	31.2%
Ischemic Heart Disease	37	5.1%
Lung Cancer	3	0.4%
Osteoporosis	8	1.1%
Prostate Cancer	6	0.8%
Rheumatoid Arthritis / Osteoarthritis	79	11.0%
Stroke / Transient Ischemic Attack	24	3.3%
Health Service Utilization Intensity:		

Table 1e: Baseline table (Olanzapine Extended Release)

Characteristic ¹	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	10.0	11.4
Mean number of emergency room encounters (ED)	2.6	3.5
Mean number of inpatient hospital encounters (IP)	0.7	1.1
Mean number of non-acute institutional encounters (IS)	0.0	0.1
Mean number of other ambulatory encounters (OA)	3.9	9.4
Mean number of filled prescriptions	16.7	17.8
Mean number of generics	6.6	6.1
Mean number of unique drug classes	6.1	5.4

¹All metrics based on total number of unique patients
²Value represents standard deviation where no % follows the value
³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051).

Table 1f: Baseline table (Panobinostat)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	155	
Demographics		
Mean Age (Years)	59.8	13.2
Age (Years): 00-17	5	3.2%
Age (Years): 18-24	-	-
Age (Years): 25-40	2	1.3%
Age (Years): 41-64	102	65.8%
Age (Years): 65+	46	29.7%
Sex (Female)	63	40.6%
Sex (Male)	92	59.4%
Year (2010)	-	-
Year (2011)	-	-
Year (2012)	-	-
Year (2013)	-	-
Year (2014)	-	-
Year (2015)	63	40.6%
Year (2016)	24	15.5%
Year (2017)	28	18.1%
Year (2018)	17	11.0%
Year (2019)	14	9.0%
Year (2020)	9	5.8%
Recorded history of:		
Prior combined comorbidity score ³	5.6	3.4
Acquired Hypothyroidism	20	12.9%
Acute Myocardial Infarction	5	3.2%
Alzheimer's Disease	1	0.6%
Alzheimer's Disease, Related Disorders, or Senile Dementia	3	1.9%
Anemia	114	73.5%
Asthma	10	6.5%
Atrial Fibrillation	13	8.4%
Benign Prostatic Hyperplasia	6	3.9%
Breast Cancer	3	1.9%
Cataracts	24	15.5%
Chronic Kidney Disease	68	43.9%
Chronic Obstructive Pulmonary Disease	23	14.8%
Colorectal Cancer	1	0.6%
Depression	21	13.5%
Diabetes	37	23.9%
Endometrial Cancer	0	0.0%
Glaucoma	15	9.7%
Heart Failure	16	10.3%
Hip / Pelvic Fracture	5	3.2%
Hyperlipidemia	34	21.9%
Hypertension	71	45.8%
Ischemic Heart Disease	22	14.2%
Lung Cancer	1	0.6%
Osteoporosis	13	8.4%
Prostate Cancer	3	1.9%
Rheumatoid Arthritis / Osteoarthritis	43	27.7%
Stroke / Transient Ischemic Attack	5	3.2%
Health Service UtilizationIntensity:		

Table 1f: Baseline table (Panobinostat)

Characteristic	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	37.3	17.6
Mean number of emergency room encounters (ED)	0.7	1.2
Mean number of inpatient hospital encounters (IP)	1.3	1.5
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	9.5	14.5
Mean number of filled prescriptions	34.2	16.2
Mean number of generics	15.3	6.1
Mean number of unique drug classes	13.9	5.1

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1g: Baseline table (Romiplostim)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	2,470	
Demographics		
Mean Age (Years)	57.0	18.1
Age (Years): 00-17	79	3.2%
Age (Years): 18-24	85	3.4%
Age (Years): 25-40	275	11.1%
Age (Years): 41-64	1,272	51.5%
Age (Years): 65+	759	30.7%
Sex (Female)	1,297	52.5%
Sex (Male)	1,173	47.5%
Year (2010)	112	4.5%
Year (2011)	282	11.4%
Year (2012)	334	13.5%
Year (2013)	269	10.9%
Year (2014)	321	13.0%
Year (2015)	261	10.6%
Year (2016)	213	8.6%
Year (2017)	175	7.1%
Year (2018)	173	7.0%
Year (2019)	176	7.1%
Year (2020)	154	6.2%
Recorded history of:		
Prior combined comorbidity score ³	3.6	3.1
Acquired Hypothyroidism	319	12.9%
Acute Myocardial Infarction	36	1.5%
Alzheimer's Disease	7	0.3%
Alzheimer's Disease, Related Disorders, or Senile Dementia	31	1.3%
Anemia	1,286	52.1%
Asthma	160	6.5%
Atrial Fibrillation	222	9.0%
Benign Prostatic Hyperplasia	136	5.5%
Breast Cancer	126	5.1%
Cataracts	215	8.7%
Chronic Kidney Disease	505	20.4%
Chronic Obstructive Pulmonary Disease	243	9.8%
Colorectal Cancer	111	4.5%
Depression	238	9.6%
Diabetes	608	24.6%
Endometrial Cancer	19	0.8%
Glaucoma	119	4.8%
Heart Failure	214	8.7%
Hip / Pelvic Fracture	16	0.6%
Hyperlipidemia	764	30.9%
Hypertension	1,164	47.1%
Ischemic Heart Disease	416	16.8%
Lung Cancer	79	3.2%
Osteoporosis	97	3.9%
Prostate Cancer	73	3.0%
Rheumatoid Arthritis / Osteoarthritis	456	18.5%
Stroke / Transient Ischemic Attack	116	4.7%
Health Service Utilization Intensity:		

Table 1g: Baseline table (Romiplostim)

Characteristic ¹	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	22.9	15.9
Mean number of emergency room encounters (ED)	0.7	1.6
Mean number of inpatient hospital encounters (IP)	0.8	1.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	5.9	10.4
Mean number of filled prescriptions	19.6	16.3
Mean number of generics	9.0	6.2
Mean number of unique drug classes	8.2	5.5

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1h: Baseline table (Teduglutide)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	205	
Demographics		
Mean Age (Years)	52.4	17.4
Age (Years): 00-17	11	5.4%
Age (Years): 18-24	6	2.9%
Age (Years): 25-40	24	11.7%
Age (Years): 41-64	127	62.0%
Age (Years): 65+	37	18.0%
Sex (Female)	132	64.4%
Sex (Male)	73	35.6%
Year (2010)	-	-
Year (2011)	-	-
Year (2012)	-	-
Year (2013)	28	13.7%
Year (2014)	24	11.7%
Year (2015)	14	6.8%
Year (2016)	32	15.6%
Year (2017)	38	18.5%
Year (2018)	26	12.7%
Year (2019)	30	14.6%
Year (2020)	13	6.3%
Recorded history of:		
Prior combined comorbidity score ³	4.5	3.0
Acquired Hypothyroidism	29	14.1%
Acute Myocardial Infarction	1	0.5%
Alzheimer's Disease	0	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	3	1.5%
Anemia	121	59.0%
Asthma	20	9.8%
Atrial Fibrillation	14	6.8%
Benign Prostatic Hyperplasia	2	1.0%
Breast Cancer	2	1.0%
Cataracts	18	8.8%
Chronic Kidney Disease	90	43.9%
Chronic Obstructive Pulmonary Disease	32	15.6%
Colorectal Cancer	11	5.4%
Depression	66	32.2%
Diabetes	30	14.6%
Endometrial Cancer	1	0.5%
Glaucoma	5	2.4%
Heart Failure	18	8.8%
Hip / Pelvic Fracture	1	0.5%
Hyperlipidemia	34	16.6%
Hypertension	92	44.9%
Ischemic Heart Disease	22	10.7%
Lung Cancer	3	1.5%
Osteoporosis	23	11.2%
Prostate Cancer	0	0.0%
Rheumatoid Arthritis / Osteoarthritis	48	23.4%
Stroke / Transient Ischemic Attack	9	4.4%
Health Service UtilizationIntensity:		

Table 1h: Baseline table (Teduglutide)

Characteristic ¹	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	23.8	17.6
Mean number of emergency room encounters (ED)	1.3	2.4
Mean number of inpatient hospital encounters (IP)	1.3	1.7
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	36.9	34.5
Mean number of filled prescriptions	30.3	27.8
Mean number of generics	12.5	6.7
Mean number of unique drug classes	11.6	6.0

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1i: Baseline table (Testosterone undecanoate)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	2,614	
Demographics		
Mean Age (Years)	52.4	10.8
Age (Years): 00-17	2	0.1%
Age (Years): 18-24	15	0.6%
Age (Years): 25-40	374	14.3%
Age (Years): 41-64	1,982	75.8%
Age (Years): 65+	241	9.2%
Sex (Female)	22	0.8%
Sex (Male)	2,592	99.2%
Year (2010)	-	-
Year (2011)	-	-
Year (2012)	-	-
Year (2013)	-	-
Year (2014)	135	5.2%
Year (2015)	741	28.3%
Year (2016)	450	17.2%
Year (2017)	380	14.5%
Year (2018)	365	14.0%
Year (2019)	328	12.5%
Year (2020)	215	8.2%
Recorded history of:		
Prior combined comorbidity score ³	0.4	1.3
Acquired Hypothyroidism	263	10.1%
Acute Myocardial Infarction	12	0.5%
Alzheimer's Disease	1	0.0%
Alzheimer's Disease, Related Disorders, or Senile Dementia	5	0.2%
Anemia	205	7.8%
Asthma	138	5.3%
Atrial Fibrillation	70	2.7%
Benign Prostatic Hyperplasia	697	26.7%
Breast Cancer	0	0.0%
Cataracts	158	6.0%
Chronic Kidney Disease	290	11.1%
Chronic Obstructive Pulmonary Disease	113	4.3%
Colorectal Cancer	13	0.5%
Depression	368	14.1%
Diabetes	543	20.8%
Endometrial Cancer	0	0.0%
Glaucoma	114	4.4%
Heart Failure	37	1.4%
Hip / Pelvic Fracture	2	0.1%
Hyperlipidemia	1,168	44.7%
Hypertension	1,135	43.4%
Ischemic Heart Disease	207	7.9%
Lung Cancer	7	0.3%
Osteoporosis	23	0.9%
Prostate Cancer	79	3.0%
Rheumatoid Arthritis / Osteoarthritis	460	17.6%
Stroke / Transient Ischemic Attack	28	1.1%
Health Service Utilization Intensity:		

Table 1i: Baseline table (Testosterone undecanoate)

Characteristic ¹	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	12.3	10.0
Mean number of emergency room encounters (ED)	0.1	0.5
Mean number of inpatient hospital encounters (IP)	0.0	0.2
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	2.5	3.5
Mean number of filled prescriptions	15.7	14.7
Mean number of generics	7.0	5.2
Mean number of unique drug classes	6.4	4.6

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).

Table 1j: Baseline table (Vigabatrin)		
Characteristic¹	N/Mean	%/Std Dev²
Number of unique patients	595	
Demographics		
Mean Age (Years)	6.8	11.0
Age (Years): 00-17	516	86.7%
Age (Years): 18-24	40	6.7%
Age (Years): 25-40	23	3.9%
Age (Years): 41-64	15	2.5%
Age (Years): 65+	1	0.2%
Sex (Female)	268	45.0%
Sex (Male)	327	55.0%
Year (2010)	53	8.9%
Year (2011)	85	14.3%
Year (2012)	64	10.8%
Year (2013)	60	10.1%
Year (2014)	55	9.2%
Year (2015)	41	6.9%
Year (2016)	59	9.9%
Year (2017)	43	7.2%
Year (2018)	55	9.2%
Year (2019)	45	7.6%
Year (2020)	35	5.9%
Recorded history of:		
Prior combined comorbidity score ³	0.8	1.3
Acquired Hypothyroidism	19	3.2%
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	1	0.2%
Alzheimer's Disease, Related Disorders, or Senile Dementia	6	1.0%
Anemia	34	5.7%
Asthma	48	8.1%
Atrial Fibrillation	0	0.0%
Benign Prostatic Hyperplasia	2	0.3%
Breast Cancer	1	0.2%
Cataracts	7	1.2%
Chronic Kidney Disease	48	8.1%
Chronic Obstructive Pulmonary Disease	21	3.5%
Colorectal Cancer	0	0.0%
Depression	11	1.8%
Diabetes	6	1.0%
Endometrial Cancer	0	0.0%
Glaucoma	11	1.8%
Heart Failure	7	1.2%
Hip / Pelvic Fracture	1	0.2%
Hyperlipidemia	9	1.5%
Hypertension	45	7.6%
Ischemic Heart Disease	0	0.0%
Lung Cancer	0	0.0%
Osteoporosis	3	0.5%
Prostate Cancer	1	0.2%
Rheumatoid Arthritis / Osteoarthritis	5	0.8%
Stroke / Transient Ischemic Attack	40	6.7%
Health Service UtilizationIntensity:		

Table 1j: Baseline table (Vigabatrin)

Characteristic ¹	N/Mean	%/Std Dev ²
Mean number of ambulatory encounters (AV)	20.4	15.4
Mean number of emergency room encounters (ED)	0.9	1.5
Mean number of inpatient hospital encounters (IP)	1.2	1.4
Mean number of non-acute institutional encounters (IS)	0.0	0.0
Mean number of other ambulatory encounters (OA)	14.4	27.8
Mean number of filled prescriptions	17.3	15.0
Mean number of generics	6.8	4.2
Mean number of unique drug classes	6.4	3.8

¹All metrics based on total number of unique patients

²Value represents standard deviation where no % follows the value

³The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. *J Clin Epidemiol.* 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. *Med Care.* 2017;55(12):1046-1051).



Table 2a: Distribution of cumulative exposure duration, by length categories, in days												
Exposures	Total Patients		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	5,261	100.0	2,069	39.3	1,095	20.8	1,243	23.6	461	8.8	393	7.5
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	156,995	100.0	123,939	78.9	7,392	4.7	14,899	9.5	6,451	4.1	4,314	2.7
Idelalisib	318	100.0	67	21.1	90	28.3	123	38.7	27	8.5	11	3.5
Olanzapine Extended Release	721	100.0	694	96.3	11	1.5	10	1.4	4	0.6	2	0.3
Panobinostat	155	100.0	46	29.7	60	38.7	46	29.7	3	1.9	0	0.0
Romiplostim	2,470	100.0	1,825	73.9	412	16.7	198	8.0	18	0.7	17	0.7
Teduglutide	205	100.0	39	19.0	45	22.0	63	30.7	36	17.6	22	10.7
Testosterone undecanoate	2,614	100.0	1,878	71.8	175	6.7	358	13.7	129	4.9	74	2.8
Vigabatrin	595	100.0	65	10.9	95	16.0	230	38.7	106	17.8	99	16.6

Table 2b: Distribution of cumulative exposure duration, by length categories, in days, by sex												
Exposures	Total Patients		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	5,261	100.0	2,069	100.0	1,095	100.0	1,243	100.0	461	100.0	393	100.0
Female	4,614	87.7	1,814	87.7	968	88.4	1,089	87.6	409	88.7	334	85.0
Male	647	12.3	255	12.3	127	11.6	154	12.4	52	11.3	59	15.0
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Female	3	42.9	3	42.9	0	0.0	0	0.0	0	0.0	0	0.0
Male	4	57.1	4	57.1	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	156,995	100.0	123,939	100.0	7,392	100.0	14,899	100.0	6,451	100.0	4,314	100.0
Female	134,414	85.6	103,642	83.6	6,531	88.4	14,057	94.3	6,101	94.6	4,083	94.6
Male	22,581	14.4	20,297	16.4	861	11.6	842	5.7	350	5.4	231	5.4
Idelalisib	318	100.0	67	100.0	90	100.0	123	100.0	27	100.0	11	100.0
Female	138	43.4	31	46.3	38	42.2	52	42.3	12	44.4	5	45.5
Male	180	56.6	36	53.7	52	57.8	71	57.7	15	55.6	6	54.5
Olanzapine Extended Release	721	100.0	694	100.0	11	100.0	10	100.0	4	100.0	2	100.0
Female	345	47.9	335	48.3	4	36.4	3	30.0	1	25.0	2	100.0
Male	376	52.1	359	51.7	7	63.6	7	70.0	3	75.0	0	0.0
Panobinostat	155	100.0	46	100.0	60	100.0	46	100.0	3	100.0	0	0.0
Female	63	40.6	16	34.8	21	35.0	25	54.3	1	33.3	0	0.0
Male	92	59.4	30	65.2	39	65.0	21	45.7	2	66.7	0	0.0
Romiplostim	2,470	100.0	1,825	100.0	412	100.0	198	100.0	18	100.0	17	100.0
Female	1,297	52.5	966	52.9	220	53.4	92	46.5	11	61.1	8	47.1
Male	1,173	47.5	859	47.1	192	46.6	106	53.5	7	38.9	9	52.9
Teduglutide	205	100.0	39	100.0	45	100.0	63	100.0	36	100.0	22	100.0
Female	132	64.4	24	61.5	30	66.7	41	65.1	22	61.1	15	68.2
Male	73	35.6	15	38.5	15	33.3	22	34.9	14	38.9	7	31.8
Testosterone undecanoate	2,614	100.0	1,878	100.0	175	100.0	358	100.0	129	100.0	74	100.0
Female	22	0.8	19	1.0	0	0.0	2	0.6	1	0.8	0	0.0
Male	2,592	99.2	1,859	99.0	175	100.0	356	99.4	128	99.2	74	100.0
Vigabatrin	595	100.0	65	100.0	95	100.0	230	100.0	106	100.0	99	100.0
Female	268	45.0	21	32.3	45	47.4	109	47.4	48	45.3	45	45.5
Male	327	55.0	44	67.7	50	52.6	121	52.6	58	54.7	54	54.5



Table 2c: Distribution of cumulative exposure duration, by length categories, in days, by age group (years)												
Exposures	Total Patients		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	5,261	100.0	2,069	100.0	1,095	100.0	1,243	100.0	461	100.0	393	100.0
00-17	30	0.6	11	0.5	7	0.6	9	0.7	2	0.4	1	0.3
18-24	363	6.9	171	8.3	64	5.8	84	6.8	28	6.1	16	4.1
25-40	1,097	20.9	474	22.9	241	22.0	248	20.0	76	16.5	58	14.8
41-64	3,073	58.4	1,136	54.9	631	57.6	736	59.2	298	64.6	272	69.2
65+	698	13.3	277	13.4	152	13.9	166	13.4	57	12.4	46	11.7
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	1	14.3	1	14.3	0	0.0	0	0.0	0	0.0	0	0.0
25-40	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
41-64	4	57.1	4	57.1	0	0.0	0	0.0	0	0.0	0	0.0
65+	2	28.6	2	28.6	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	156,995	100.0	123,939	100.0	7,392	100.0	14,899	100.0	6,451	100.0	4,314	100.0
00-17	37	0.0	34	0.0	2	0.0	1	0.0	0	0.0	0	0.0
18-24	118	0.1	108	0.1	2	0.0	8	0.1	0	0.0	0	0.0
25-40	1,772	1.1	1,571	1.3	93	1.3	66	0.4	27	0.4	15	0.3
41-64	80,140	51.0	61,369	49.5	4,263	57.7	8,348	56.0	3,852	59.7	2,308	53.5
65+	74,928	47.7	60,857	49.1	3,032	41.0	6,476	43.5	2,572	39.9	1,991	46.2
Idelalisib	318	100.0	67	100.0	90	100.0	123	100.0	27	100.0	11	100.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	4	1.3	1	1.5	0	0.0	1	0.8	1	3.7	1	9.1
41-64	151	47.5	26	38.8	46	51.1	66	53.7	10	37.0	3	27.3
65+	163	51.3	40	59.7	44	48.9	56	45.5	16	59.3	7	63.6
Olanzapine Extended Release	721	100.0	694	100.0	11	100.0	10	100.0	4	100.0	2	100.0
00-17	73	10.1	73	10.5	0	0.0	0	0.0	0	0.0	0	0.0
18-24	190	26.4	180	25.9	4	36.4	4	40.0	2	50.0	0	0.0
25-40	164	22.7	158	22.8	1	9.1	3	30.0	1	25.0	1	50.0
41-64	201	27.9	191	27.5	5	45.5	3	30.0	1	25.0	1	50.0
65+	93	12.9	92	13.3	1	9.1	0	0.0	0	0.0	0	0.0
Panobinostat	155	100.0	46	100.0	60	100.0	46	100.0	3	100.0	0	0.0
00-17	5	3.2	2	4.3	3	5.0	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	2	1.3	0	0.0	2	3.3	0	0.0	0	0.0	0	0.0
41-64	102	65.8	31	67.4	37	61.7	31	67.4	3	100.0	0	0.0
65+	46	29.7	13	28.3	18	30.0	15	32.6	0	0.0	0	0.0
Romiplostim	2,470	100.0	1,825	100.0	412	100.0	198	100.0	18	100.0	17	100.0

Table 2c: Distribution of cumulative exposure duration, by length categories, in days, by age group (years)												
Exposures	Total Patients		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
00-17	79	3.2	47	2.6	14	3.4	11	5.6	4	22.2	3	17.6
18-24	85	3.4	61	3.3	14	3.4	8	4.0	2	11.1	0	0.0
25-40	275	11.1	223	12.2	34	8.3	15	7.6	3	16.7	0	0.0
41-64	1,272	51.5	974	53.4	201	48.8	83	41.9	3	16.7	11	64.7
65+	759	30.7	520	28.5	149	36.2	81	40.9	6	33.3	3	17.6
Teduglutide	205	100.0	39	100.0	45	100.0	63	100.0	36	100.0	22	100.0
00-17	11	5.4	1	2.6	2	4.4	6	9.5	2	5.6	0	0.0
18-24	6	2.9	2	5.1	3	6.7	0	0.0	0	0.0	1	4.5
25-40	24	11.7	2	5.1	6	13.3	10	15.9	4	11.1	2	9.1
41-64	127	62.0	26	66.7	27	60.0	33	52.4	26	72.2	15	68.2
65+	37	18.0	8	20.5	7	15.6	14	22.2	4	11.1	4	18.2
Testosterone undecanoate	2,614	100.0	1,878	100.0	175	100.0	358	100.0	129	100.0	74	100.0
00-17	2	0.1	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0
18-24	15	0.6	9	0.5	1	0.6	4	1.1	1	0.8	0	0.0
25-40	374	14.3	273	14.5	32	18.3	51	14.2	15	11.6	3	4.1
41-64	1,982	75.8	1,387	73.9	133	76.0	287	80.2	108	83.7	67	90.5
65+	241	9.2	207	11.0	9	5.1	16	4.5	5	3.9	4	5.4
Vigabatrin	595	100.0	65	100.0	95	100.0	230	100.0	106	100.0	99	100.0
00-17	516	86.7	53	81.5	79	83.2	207	90.0	94	88.7	83	83.8
18-24	40	6.7	8	12.3	7	7.4	12	5.2	5	4.7	8	8.1
25-40	23	3.9	1	1.5	7	7.4	6	2.6	2	1.9	7	7.1
41-64	15	2.5	2	3.1	2	2.1	5	2.2	5	4.7	1	1.0
65+	1	0.2	1	1.5	0	0.0	0	0.0	0	0.0	0	0.0

Table 3a: Descriptive statistics of cumulative exposure duration, all episodes, in days								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	5,261	212.91	360.51	1	30	60	210	3,341
Alvimopan	7	3.00	2.31	1	1	3	5	7
Denosumab	156,995	79.50	219.34	1	2	4	17	2,845
Idelalisib	318	176.74	218.66	2	58	99	210	1,760
Olanzapine Extended Release	721	13.43	118.17	1	1	1	1	2,726
Panobinostat	155	91.57	101.63	5	28	63	112	719
Romiplostim	2,470	39.90	115.33	1	3	10	32	2,138
Teduglutide	205	302.15	384.57	1	60	150	409	2,638
Testosterone undecanoate	2,614	91.08	209.43	1	3	7	58	1,718
Vigabatrin	595	413.67	529.27	5	90	210	510	3,407

Table 3b: Descriptive statistics of cumulative exposure duration, all episodes, in days, by sex								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	5,261	212.91	360.51	1	30	60	210	3,341
Female	4,614	209.66	352.16	1	30	60	210	3,341
Male	647	236.10	414.75	1	30	60	240	3,043
Alvimopan	7	3.00	2.31	1	1	3	5	7
Female	3	2.33	2.31	1	1	1	5	5
Male	4	3.50	2.52	1	2	3	5	7
Denosumab	156,995	79.50	219.34	1	2	4	17	2,845
Female	134,414	86.95	229.10	1	2	4	27	2,845
Male	22,581	35.13	140.51	1	2	4	11	2,178
Idelalisib	318	176.74	218.66	2	58	99	210	1,760
Female	138	176.28	217.93	11	45	92	210	1,260
Male	180	177.09	219.83	2	60	102	197	1,760
Olanzapine Extended Release	721	13.43	118.17	1	1	1	1	2,726
Female	345	16.34	159.78	1	1	1	1	2,726
Male	376	10.76	58.13	1	1	1	1	721
Panobinostat	155	91.57	101.63	5	28	63	112	719
Female	63	105.65	110.06	5	30	70	126	669
Male	92	81.93	94.85	12	24	60	96	719
Romiplostim	2,470	39.90	115.33	1	3	10	32	2,138
Female	1,297	38.60	105.05	1	3	10	31	1,500
Male	1,173	41.34	125.76	1	3	10	34	2,138
Teduglutide	205	302.15	384.57	1	60	150	409	2,638
Female	132	308.97	391.20	1	60	173	421	2,638
Male	73	289.82	374.64	18	59	150	394	2,042
Testosterone undecanoate	2,614	91.08	209.43	1	3	7	58	1,718
Female	22	50.32	155.23	1	1	1	7	710
Male	2,592	91.42	209.82	1	3	7	59	1,718
Vigabatrin	595	413.67	529.27	5	90	210	510	3,407
Female	268	416.04	522.62	15	91	210	510	3,407
Male	327	411.73	535.45	5	90	218	494	3,202

Table 3c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	5,261	212.91	360.51	1	30	60	210	3,341
00-17	30	164.13	242.61	30	30	68	150	1,127
18-24	363	157.66	261.34	1	30	60	150	1,860
25-40	1,097	174.67	326.45	1	30	60	150	3,295
41-64	3,073	236.98	387.72	1	30	69	249	3,341
65+	698	197.84	325.52	1	30	60	210	2,324
Alvimopan	7	3.00	2.31	1	1	3	5	7
00-17	0	-	-	-	-	-	-	-
18-24	1	5.00	-	5	5	5	5	5
25-40	0	-	-	-	-	-	-	-
41-64	4	3.00	2.83	1	1	2	5	7
65+	2	2.00	1.41	1	1	2	3	3
Denosumab	156,995	79.50	219.34	1	2	4	17	2,845
00-17	37	13.62	33.17	1	2	5	12	198
18-24	118	20.26	57.32	1	1	3	8	336
25-40	1,772	33.45	130.78	1	2	4	12	2,062
41-64	80,140	86.61	223.55	1	2	4	30	2,845
65+	74,928	73.11	216.31	1	2	4	12	2,807
Idelalisib	318	176.74	218.66	2	58	99	210	1,760
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	4	461.00	434.29	14	97	450	825	930
41-64	151	161.96	184.11	2	60	115	180	1,260
65+	163	183.46	237.57	5	31	90	210	1,760
Olanzapine Extended Release	721	13.43	118.17	1	1	1	1	2,726
00-17	73	1.51	3.16	1	1	1	1	28
18-24	190	14.26	70.78	1	1	1	1	721
25-40	164	14.07	89.12	1	1	1	1	982
41-64	201	21.78	197.14	1	1	1	1	2,726
65+	93	1.94	5.85	1	1	1	1	56
Panobinostat	155	91.57	101.63	5	28	63	112	719
00-17	5	46.20	27.00	21	28	42	50	90
18-24	0	-	-	-	-	-	-	-
25-40	2	52.50	14.85	42	42	53	63	63
41-64	102	98.57	115.06	5	28	63	112	719
65+	46	82.70	71.27	12	28	57	105	304
Romiplostim	2,470	39.90	115.33	1	3	10	32	2,138
00-17	79	116.34	257.86	1	6	22	84	1,549

Table 3c: Descriptive statistics of cumulative exposure duration, all episodes, in days, by age group (years)								
Exposures	Total Patients	Mean	STD	Min	Q1	Median	Q3	Max
18-24	85	40.45	78.52	1	3	9	35	397
25-40	275	28.24	66.38	1	3	8	24	607
41-64	1,272	36.97	123.87	1	3	9	28	2,138
65+	759	41.03	88.33	1	4	12	43	1,172
Teduglutide	205	302.15	384.57	1	60	150	409	2,638
00-17	11	229.55	133.38	30	82	235	353	409
18-24	6	309.50	657.02	7	30	55	60	1,650
25-40	24	273.25	316.72	30	71	135	378	1,335
41-64	127	305.24	361.94	1	60	150	468	2,042
65+	37	330.68	497.54	1	60	210	344	2,638
Testosterone undecanoate	2,614	91.08	209.43	1	3	7	58	1,718
00-17	2	3.00	1.41	2	2	3	4	4
18-24	15	118.00	196.50	1	2	7	232	710
25-40	374	64.50	146.98	1	2	7	58	1,238
41-64	1,982	101.57	225.55	1	3	7	82	1,718
65+	241	45.08	132.46	1	3	6	15	938
Vigabatrin	595	413.67	529.27	5	90	210	510	3,407
00-17	516	412.61	527.71	5	90	214	510	3,407
18-24	40	398.75	491.47	14	60	225	536	1,757
25-40	23	546.61	719.94	16	90	240	806	3,090
41-64	15	311.60	320.25	30	60	200	390	1,268
65+	1	30.00	-	30	30	30	30	30

Table 4a: Distribution of first exposure episode duration, by length categories, in days												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	5,261	100.0	3,963	75.3	894	17.0	331	6.3	47	0.9	26	0.5
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	156,995	100.0	136,317	86.8	6,668	4.2	13,142	8.4	734	0.5	134	0.1
Idelalisib	318	100.0	171	53.8	89	28.0	53	16.7	4	1.3	1	0.3
Olanzapine Extended Release	721	100.0	711	98.6	9	1.2	1	0.1	0	0.0	0	0.0
Panobinostat	155	100.0	97	62.6	49	31.6	9	5.8	0	0.0	0	0.0
Romiplostim	2,470	100.0	2,414	97.7	38	1.5	14	0.6	1	0.0	3	0.1
Teduglutide	205	100.0	116	56.6	58	28.3	24	11.7	6	2.9	1	0.5
Testosterone undecanoate	2,614	100.0	2,370	90.7	127	4.9	106	4.1	8	0.3	3	0.1
Vigabatrin	595	100.0	281	47.2	146	24.5	128	21.5	30	5.0	10	1.7

Table 4b: Distribution of first exposure episode duration, by length categories, in days, by sex												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	5,261	100.0	3,963	100.0	894	100.0	331	100.0	47	100.0	26	100.0
Female	4,614	87.7	3,487	88.0	779	87.1	278	84.0	45	95.7	25	96.2
Male	647	12.3	476	12.0	115	12.9	53	16.0	2	4.3	1	3.8
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Female	3	42.9	3	42.9	0	0.0	0	0.0	0	0.0	0	0.0
Male	4	57.1	4	57.1	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	156,995	100.0	136,317	100.0	6,668	100.0	13,142	100.0	734	100.0	134	100.0
Female	134,414	85.6	114,928	84.3	6,294	94.4	12,393	94.3	677	92.2	122	91.0
Male	22,581	14.4	21,389	15.7	374	5.6	749	5.7	57	7.8	12	9.0
Idelalisib	318	100.0	171	100.0	89	100.0	53	100.0	4	100.0	1	100.0
Female	138	43.4	80	46.8	31	34.8	25	47.2	2	50.0	0	0.0
Male	180	56.6	91	53.2	58	65.2	28	52.8	2	50.0	1	100.0
Olanzapine Extended Release	721	100.0	711	100.0	9	100.0	1	100.0	0	0.0	0	0.0
Female	345	47.9	340	47.8	5	55.6	0	0.0	0	0.0	0	0.0
Male	376	52.1	371	52.2	4	44.4	1	100.0	0	0.0	0	0.0
Panobinostat	155	100.0	97	100.0	49	100.0	9	100.0	0	0.0	0	0.0
Female	63	40.6	36	37.1	19	38.8	8	88.9	0	0.0	0	0.0
Male	92	59.4	61	62.9	30	61.2	1	11.1	0	0.0	0	0.0
Romiplostim	2,470	100.0	2,414	100.0	38	100.0	14	100.0	1	100.0	3	100.0
Female	1,297	52.5	1,273	52.7	17	44.7	5	35.7	0	0.0	2	66.7
Male	1,173	47.5	1,141	47.3	21	55.3	9	64.3	1	100.0	1	33.3
Teduglutide	205	100.0	116	100.0	58	100.0	24	100.0	6	100.0	1	100.0
Female	132	64.4	77	66.4	36	62.1	15	62.5	3	50.0	1	100.0
Male	73	35.6	39	33.6	22	37.9	9	37.5	3	50.0	0	0.0
Testosterone undecanoate	2,614	100.0	2,370	100.0	127	100.0	106	100.0	8	100.0	3	100.0
Female	22	0.8	22	0.9	0	0.0	0	0.0	0	0.0	0	0.0
Male	2,592	99.2	2,348	99.1	127	100.0	106	100.0	8	100.0	3	100.0
Vigabatrin	595	100.0	281	100.0	146	100.0	128	100.0	30	100.0	10	100.0
Female	268	45.0	120	42.7	70	47.9	59	46.1	15	50.0	4	40.0
Male	327	55.0	161	57.3	76	52.1	69	53.9	15	50.0	6	60.0

Table 4c: Distribution of first exposure episode duration, by length categories, in days, by age group (years)												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	5,261	100.0	3,963	100.0	894	100.0	331	100.0	47	100.0	26	100.0
00-17	30	0.6	25	0.6	4	0.4	1	0.3	0	0.0	0	0.0
18-24	363	6.9	298	7.5	48	5.4	12	3.6	4	8.5	1	3.8
25-40	1,097	20.9	881	22.2	160	17.9	52	15.7	2	4.3	2	7.7
41-64	3,073	58.4	2,266	57.2	544	60.9	207	62.5	36	76.6	20	76.9
65+	698	13.3	493	12.4	138	15.4	59	17.8	5	10.6	3	11.5
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	1	14.3	1	14.3	0	0.0	0	0.0	0	0.0	0	0.0
25-40	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
41-64	4	57.1	4	57.1	0	0.0	0	0.0	0	0.0	0	0.0
65+	2	28.6	2	28.6	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	156,995	100.0	136,317	100.0	6,668	100.0	13,142	100.0	734	100.0	134	100.0
00-17	37	0.0	37	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	118	0.1	111	0.1	5	0.1	2	0.0	0	0.0	0	0.0
25-40	1,772	1.1	1,677	1.2	37	0.6	57	0.4	1	0.1	0	0.0
41-64	80,140	51.0	68,653	50.4	4,109	61.6	6,949	52.9	393	53.5	36	26.9
65+	74,928	47.7	65,839	48.3	2,517	37.7	6,134	46.7	340	46.3	98	73.1
Idelalisib	318	100.0	171	100.0	89	100.0	53	100.0	4	100.0	1	100.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	4	1.3	2	1.2	0	0.0	2	3.8	0	0.0	0	0.0
41-64	151	47.5	72	42.1	54	60.7	24	45.3	1	25.0	0	0.0
65+	163	51.3	97	56.7	35	39.3	27	50.9	3	75.0	1	100.0
Olanzapine Extended Release	721	100.0	711	100.0	9	100.0	1	100.0	0	0.0	0	0.0
00-17	73	10.1	73	10.3	0	0.0	0	0.0	0	0.0	0	0.0
18-24	190	26.4	187	26.3	3	33.3	0	0.0	0	0.0	0	0.0
25-40	164	22.7	162	22.8	2	22.2	0	0.0	0	0.0	0	0.0
41-64	201	27.9	196	27.6	4	44.4	1	100.0	0	0.0	0	0.0
65+	93	12.9	93	13.1	0	0.0	0	0.0	0	0.0	0	0.0
Panobinostat	155	100.0	97	100.0	49	100.0	9	100.0	0	0.0	0	0.0
00-17	5	3.2	2	2.1	3	6.1	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	2	1.3	0	0.0	2	4.1	0	0.0	0	0.0	0	0.0
41-64	102	65.8	69	71.1	31	63.3	2	22.2	0	0.0	0	0.0
65+	46	29.7	26	26.8	13	26.5	7	77.8	0	0.0	0	0.0
Romiplostim	2,470	100.0	2,414	100.0	38	100.0	14	100.0	1	100.0	3	100.0

Table 4c: Distribution of first exposure episode duration, by length categories, in days, by age group (years)												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
00-17	79	3.2	71	2.9	5	13.2	2	14.3	1	100.0	0	0.0
18-24	85	3.4	80	3.3	2	5.3	3	21.4	0	0.0	0	0.0
25-40	275	11.1	272	11.3	2	5.3	1	7.1	0	0.0	0	0.0
41-64	1,272	51.5	1,251	51.8	14	36.8	5	35.7	0	0.0	2	66.7
65+	759	30.7	740	30.7	15	39.5	3	21.4	0	0.0	1	33.3
Teduglutide	205	100.0	116	100.0	58	100.0	24	100.0	6	100.0	1	100.0
00-17	11	5.4	7	6.0	3	5.2	1	4.2	0	0.0	0	0.0
18-24	6	2.9	2	1.7	4	6.9	0	0.0	0	0.0	0	0.0
25-40	24	11.7	13	11.2	7	12.1	3	12.5	1	16.7	0	0.0
41-64	127	62.0	74	63.8	30	51.7	17	70.8	5	83.3	1	100.0
65+	37	18.0	20	17.2	14	24.1	3	12.5	0	0.0	0	0.0
Testosterone undecanoate	2,614	100.0	2,370	100.0	127	100.0	106	100.0	8	100.0	3	100.0
00-17	2	0.1	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0
18-24	15	0.6	12	0.5	1	0.8	2	1.9	0	0.0	0	0.0
25-40	374	14.3	337	14.2	22	17.3	13	12.3	2	25.0	0	0.0
41-64	1,982	75.8	1,790	75.5	98	77.2	85	80.2	6	75.0	3	100.0
65+	241	9.2	229	9.7	6	4.7	6	5.7	0	0.0	0	0.0
Vigabatrin	595	100.0	281	100.0	146	100.0	128	100.0	30	100.0	10	100.0
00-17	516	86.7	241	85.8	127	87.0	113	88.3	25	83.3	10	100.0
18-24	40	6.7	22	7.8	8	5.5	8	6.3	2	6.7	0	0.0
25-40	23	3.9	9	3.2	9	6.2	4	3.1	1	3.3	0	0.0
41-64	15	2.5	8	2.8	2	1.4	3	2.3	2	6.7	0	0.0
65+	1	0.2	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0

Table 5a: Descriptive statistics of first exposure episode duration, in days									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Alosetron	5,261	55.73	109.61	1	30	30	30	3,341	
Alvimopan	7	3.00	2.31	1	1	3	5	7	
Denosumab	156,995	25.50	73.94	1	1	1	1	2,001	
Idelalisib	318	73.32	124.85	2	30	30	60	1,760	
Olanzapine Extended Release	721	2.79	8.55	1	1	1	1	112	
Panobinostat	155	39.98	39.36	5	21	28	42	304	
Romiplostim	2,470	5.17	40.52	1	1	1	1	1,304	
Teduglutide	205	74.62	100.78	1	30	30	90	883	
Testosterone undecanoate	2,614	17.70	52.50	1	1	1	28	1,048	
Vigabatrin	595	112.46	167.84	3	30	60	120	1,444	

Table 5b: Descriptive statistics of first exposure episode duration, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	5,261	55.73	109.61	1	30	30	30	3,341
Female	4,614	56.23	114.03	1	30	30	30	3,341
Male	647	52.18	70.49	1	30	30	50	1,110
Alvimopan	7	3.00	2.31	1	1	3	5	7
Female	3	2.33	2.31	1	1	1	5	5
Male	4	3.50	2.52	1	2	3	5	7
Denosumab	156,995	25.50	73.94	1	1	1	1	2,001
Female	134,414	27.88	76.49	1	1	1	1	2,000
Male	22,581	11.38	54.32	1	1	1	1	2,001
Idelalisib	318	73.32	124.85	2	30	30	60	1,760
Female	138	70.46	85.03	11	30	30	77	630
Male	180	75.52	148.54	2	30	30	60	1,760
Olanzapine Extended Release	721	2.79	8.55	1	1	1	1	112
Female	345	2.28	7.35	1	1	1	1	84
Male	376	3.26	9.52	1	1	1	1	112
Panobinostat	155	39.98	39.36	5	21	28	42	304
Female	63	49.94	55.42	5	21	28	60	304
Male	92	33.16	20.35	6	21	25	42	105
Romiplostim	2,470	5.17	40.52	1	1	1	1	1,304
Female	1,297	4.88	45.17	1	1	1	1	1,304
Male	1,173	5.49	34.68	1	1	1	1	840
Teduglutide	205	74.62	100.78	1	30	30	90	883
Female	132	75.08	108.23	1	30	30	88	883
Male	73	73.78	86.38	18	30	30	90	480
Testosterone undecanoate	2,614	17.70	52.50	1	1	1	28	1,048
Female	22	4.77	9.72	1	1	1	1	30
Male	2,592	17.81	52.71	1	1	1	28	1,048
Vigabatrin	595	112.46	167.84	3	30	60	120	1,444
Female	268	114.44	165.82	7	30	60	120	1,444
Male	327	110.83	169.71	3	30	44	120	1,288

Table 5c: Descriptive statistics of first exposure episode duration, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	5,261	55.73	109.61	1	30	30	30	3,341
00-17	30	44.90	56.27	15	30	30	30	330
18-24	363	46.63	77.83	1	30	30	30	1,009
25-40	1,097	44.89	72.29	1	30	30	30	1,650
41-64	3,073	60.29	125.73	1	30	30	57	3,341
65+	698	57.90	95.78	1	30	30	60	1,620
Alvimopan	7	3.00	2.31	1	1	3	5	7
00-17	0	-	-	-	-	-	-	-
18-24	1	5.00	-	5	5	5	5	5
25-40	0	-	-	-	-	-	-	-
41-64	4	3.00	2.83	1	1	2	5	7
65+	2	2.00	1.41	1	1	2	3	3
Denosumab	156,995	25.50	73.94	1	1	1	1	2,001
00-17	37	2.51	6.42	1	1	1	1	30
18-24	118	7.12	24.50	1	1	1	1	168
25-40	1,772	9.99	39.99	1	1	1	1	450
41-64	80,140	26.73	71.43	1	1	1	1	1,885
65+	74,928	24.60	77.15	1	1	1	1	2,001
Idelalisib	318	73.32	124.85	2	30	30	60	1,760
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	4	123.50	123.00	14	22	105	225	270
41-64	151	65.32	69.10	2	30	60	60	630
65+	163	79.50	160.13	5	30	30	89	1,760
Olanzapine Extended Release	721	2.79	8.55	1	1	1	1	112
00-17	73	1.41	3.16	1	1	1	1	28
18-24	190	3.43	8.61	1	1	1	1	60
25-40	164	2.60	7.13	1	1	1	1	56
41-64	201	3.42	11.91	1	1	1	1	112
65+	93	1.54	3.11	1	1	1	1	28
Panobinostat	155	39.98	39.36	5	21	28	42	304
00-17	5	44.60	26.96	21	28	42	42	90
18-24	0	-	-	-	-	-	-	-
25-40	2	52.50	14.85	42	42	53	63	63
41-64	102	35.35	32.29	5	21	21	42	252
65+	46	49.20	52.42	12	21	28	57	304
Romiplostim	2,470	5.17	40.52	1	1	1	1	1,304
00-17	79	21.20	66.74	1	1	1	1	420



Table 5c: Descriptive statistics of first exposure episode duration, in days, by age group (years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
18-24	85	9.29	37.08	1	1	1	1	252	
25-40	275	2.28	9.43	1	1	1	1	112	
41-64	1,272	4.64	45.60	1	1	1	1	1,304	
65+	759	4.98	34.44	1	1	1	1	840	
Teduglutide	205	74.62	100.78	1	30	30	90	883	
00-17	11	48.36	29.82	30	30	30	60	120	
18-24	6	44.50	21.76	7	30	55	60	60	
25-40	24	73.92	83.63	8	30	30	90	390	
41-64	127	84.14	119.50	1	30	30	90	883	
65+	37	55.08	41.43	1	30	30	63	210	
Testosterone undecanoate	2,614	17.70	52.50	1	1	1	28	1,048	
00-17	2	1.00	0.00	1	1	1	1	1	
18-24	15	29.67	53.37	1	1	1	30	194	
25-40	374	16.48	41.40	1	1	1	28	448	
41-64	1,982	19.01	56.39	1	1	1	28	1,048	
65+	241	8.22	28.59	1	1	1	1	238	
Vigabatrin	595	112.46	167.84	3	30	60	120	1,444	
00-17	516	115.08	174.28	3	30	60	120	1,444	
18-24	40	94.55	117.11	14	30	30	105	570	
25-40	23	91.48	116.19	16	30	60	90	570	
41-64	15	107.87	126.82	30	30	30	174	390	
65+	1	30.00	-	30	30	30	30	30	

Table 6a: Distribution of second and subsequent exposure episode duration, by length categories, in days												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	13,433	100.0	9,138	68.0	3,019	22.5	1,051	7.8	167	1.2	58	0.4
Alvimopan	0	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	516,921	100.0	470,559	91.0	17,608	3.4	27,428	5.3	1,143	0.2	183	0.0
Idelalisib	541	100.0	333	61.6	151	27.9	52	9.6	4	0.7	1	0.2
Olanzapine Extended Release	217	100.0	167	77.0	31	14.3	15	6.9	4	1.8	0	0.0
Panobinostat	188	100.0	123	65.4	48	25.5	16	8.5	1	0.5	0	0.0
Romiplostim	54,279	100.0	54,094	99.7	113	0.2	59	0.1	10	0.0	3	0.0
Teduglutide	659	100.0	383	58.1	181	27.5	83	12.6	9	1.4	3	0.5
Testosterone undecanoate	12,059	100.0	10,824	89.8	754	6.3	452	3.7	29	0.2	0	0.0
Vigabatrin	1,740	100.0	828	47.6	504	29.0	332	19.1	48	2.8	28	1.6

Table 6b: Distribution of second and subsequent exposure episode duration, by length categories, in days, by sex												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	13,433	100.0	9,138	100.0	3,019	100.0	1,051	100.0	167	100.0	58	100.0
Female	11,759	87.5	8,088	88.5	2,597	86.0	882	83.9	149	89.2	43	74.1
Male	1,674	12.5	1,050	11.5	422	14.0	169	16.1	18	10.8	15	25.9
Alvimopan	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Female	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Male	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	516,921	100.0	470,559	100.0	17,608	100.0	27,428	100.0	1,143	100.0	183	100.0
Female	401,188	77.6	357,226	75.9	16,765	95.2	25,946	94.6	1,079	94.4	172	94.0
Male	115,733	22.4	113,333	24.1	843	4.8	1,482	5.4	64	5.6	11	6.0
Idelalisib	541	100.0	333	100.0	151	100.0	52	100.0	4	100.0	1	100.0
Female	254	47.0	159	47.7	69	45.7	25	48.1	1	25.0	0	0.0
Male	287	53.0	174	52.3	82	54.3	27	51.9	3	75.0	1	100.0
Olanzapine Extended Release	217	100.0	167	100.0	31	100.0	15	100.0	4	100.0	0	0.0
Female	133	61.3	102	61.1	17	54.8	12	80.0	2	50.0	0	0.0
Male	84	38.7	65	38.9	14	45.2	3	20.0	2	50.0	0	0.0
Panobinostat	188	100.0	123	100.0	48	100.0	16	100.0	1	100.0	0	0.0
Female	83	44.1	61	49.6	12	25.0	10	62.5	0	0.0	0	0.0
Male	105	55.9	62	50.4	36	75.0	6	37.5	1	100.0	0	0.0
Romiplostim	54,279	100.0	54,094	100.0	113	100.0	59	100.0	10	100.0	3	100.0
Female	28,085	51.7	27,991	51.7	60	53.1	28	47.5	6	60.0	0	0.0
Male	26,194	48.3	26,103	48.3	53	46.9	31	52.5	4	40.0	3	100.0
Teduglutide	659	100.0	383	100.0	181	100.0	83	100.0	9	100.0	3	100.0
Female	416	63.1	246	64.2	103	56.9	58	69.9	7	77.8	2	66.7
Male	243	36.9	137	35.8	78	43.1	25	30.1	2	22.2	1	33.3
Testosterone undecanoate	12,059	100.0	10,824	100.0	754	100.0	452	100.0	29	100.0	0	0.0
Female	51	0.4	44	0.4	2	0.3	5	1.1	0	0.0	0	0.0
Male	12,008	99.6	10,780	99.6	752	99.7	447	98.9	29	100.0	0	0.0
Vigabatrin	1,740	100.0	828	100.0	504	100.0	332	100.0	48	100.0	28	100.0
Female	779	44.8	370	44.7	221	43.8	154	46.4	19	39.6	15	53.6
Male	961	55.2	458	55.3	283	56.2	178	53.6	29	60.4	13	46.4



Table 6c: Distribution of second and subsequent exposure episode duration, by length categories, in days, by age group (years)												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	13,433	100.0	9,138	100.0	3,019	100.0	1,051	100.0	167	100.0	58	100.0
00-17	64	0.5	44	0.5	13	0.4	6	0.6	1	0.6	0	0.0
18-24	779	5.8	560	6.1	168	5.6	43	4.1	6	3.6	2	3.4
25-40	2,559	19.1	1,865	20.4	487	16.1	173	16.5	23	13.8	11	19.0
41-64	8,571	63.8	5,736	62.8	1,983	65.7	705	67.1	108	64.7	39	67.2
65+	1,460	10.9	933	10.2	368	12.2	124	11.8	29	17.4	6	10.3
Alvimopan	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
41-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65+	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	516,921	100.0	470,559	100.0	17,608	100.0	27,428	100.0	1,143	100.0	183	100.0
00-17	242	0.0	241	0.1	0	0.0	1	0.0	0	0.0	0	0.0
18-24	441	0.1	431	0.1	8	0.0	2	0.0	0	0.0	0	0.0
25-40	10,216	2.0	10,018	2.1	87	0.5	108	0.4	2	0.2	1	0.5
41-64	268,638	52.0	240,672	51.1	12,351	70.1	14,987	54.6	553	48.4	75	41.0
65+	237,384	45.9	219,197	46.6	5,162	29.3	12,330	45.0	588	51.4	107	58.5
Idelalisib	541	100.0	333	100.0	151	100.0	52	100.0	4	100.0	1	100.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	30	5.5	24	7.2	5	3.3	1	1.9	0	0.0	0	0.0
41-64	258	47.7	160	48.0	76	50.3	20	38.5	1	25.0	1	100.0
65+	253	46.8	149	44.7	70	46.4	31	59.6	3	75.0	0	0.0
Olanzapine Extended Release	217	100.0	167	100.0	31	100.0	15	100.0	4	100.0	0	0.0
00-17	7	3.2	7	4.2	0	0.0	0	0.0	0	0.0	0	0.0
18-24	74	34.1	63	37.7	6	19.4	4	26.7	1	25.0	0	0.0
25-40	47	21.7	31	18.6	11	35.5	5	33.3	0	0.0	0	0.0
41-64	79	36.4	56	33.5	14	45.2	6	40.0	3	75.0	0	0.0
65+	10	4.6	10	6.0	0	0.0	0	0.0	0	0.0	0	0.0
Panobinostat	188	100.0	123	100.0	48	100.0	16	100.0	1	100.0	0	0.0
00-17	1	0.5	1	0.8	0	0.0	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
41-64	145	77.1	94	76.4	38	79.2	12	75.0	1	100.0	0	0.0
65+	42	22.3	28	22.8	10	20.8	4	25.0	0	0.0	0	0.0
Romiplostim	54,279	100.0	54,094	100.0	113	100.0	59	100.0	10	100.0	3	100.0



Table 6c: Distribution of second and subsequent exposure episode duration, by length categories, in days, by age group (years)												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
00-17	1,224	2.3	1,198	2.2	12	10.6	11	18.6	2	20.0	1	33.3
18-24	1,352	2.5	1,339	2.5	8	7.1	5	8.5	0	0.0	0	0.0
25-40	5,070	9.3	5,053	9.3	14	12.4	3	5.1	0	0.0	0	0.0
41-64	26,673	49.1	26,597	49.2	42	37.2	26	44.1	6	60.0	2	66.7
65+	19,960	36.8	19,907	36.8	37	32.7	14	23.7	2	20.0	0	0.0
Teduglutide	659	100.0	383	100.0	181	100.0	83	100.0	9	100.0	3	100.0
00-17	25	3.8	10	2.6	10	5.5	5	6.0	0	0.0	0	0.0
18-24	15	2.3	9	2.3	0	0.0	6	7.2	0	0.0	0	0.0
25-40	88	13.4	56	14.6	27	14.9	4	4.8	1	11.1	0	0.0
41-64	411	62.4	246	64.2	109	60.2	50	60.2	4	44.4	2	66.7
65+	120	18.2	62	16.2	35	19.3	18	21.7	4	44.4	1	33.3
Testosterone undecanoate	12,059	100.0	10,824	100.0	754	100.0	452	100.0	29	100.0	0	0.0
00-17	4	0.0	4	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	70	0.6	59	0.5	8	1.1	3	0.7	0	0.0	0	0.0
25-40	1,631	13.5	1,520	14.0	70	9.3	39	8.6	2	6.9	0	0.0
41-64	8,948	74.2	7,891	72.9	642	85.1	388	85.8	27	93.1	0	0.0
65+	1,406	11.7	1,350	12.5	34	4.5	22	4.9	0	0.0	0	0.0
Vigabatrin	1,740	100.0	828	100.0	504	100.0	332	100.0	48	100.0	28	100.0
00-17	1,516	87.1	737	89.0	435	86.3	280	84.3	40	83.3	24	85.7
18-24	111	6.4	48	5.8	35	6.9	23	6.9	3	6.3	2	7.1
25-40	91	5.2	35	4.2	29	5.8	21	6.3	5	10.4	1	3.6
41-64	22	1.3	8	1.0	5	1.0	8	2.4	0	0.0	1	3.6
65+	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

Table 7a: Descriptive statistics of second and subsequent exposure episode duration, in days									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Alosetron	13,433	61.56	103.81	1	30	30	60	3,041	
Alvimopan	0	-	-	-	-	-	-	-	
Denosumab	516,921	16.40	56.81	1	1	1	1	2,447	
Idelalisib	541	60.79	74.24	2	30	30	60	810	
Olanzapine Extended Release	217	35.35	83.08	1	1	14	28	720	
Panobinostat	188	42.54	50.35	6	21	28	42	488	
Romiplostim	54,279	1.58	12.30	1	1	1	1	978	
Teduglutide	659	70.78	104.15	1	30	30	60	1,142	
Testosterone undecanoate	12,059	15.91	44.64	1	1	1	1	700	
Vigabatrin	1,740	103.00	174.56	1	30	60	90	2,526	

Table 7b: Descriptive statistics of second and subsequent exposure episode duration, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	13,433	61.56	103.81	1	30	30	60	3,041
Female	11,759	60.20	100.80	1	30	30	60	3,041
Male	1,674	71.08	122.52	1	30	30	60	1,676
Alvimopan	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Denosumab	516,921	16.40	56.81	1	1	1	1	2,447
Female	401,188	19.79	62.21	1	1	1	1	2,447
Male	115,733	4.63	28.63	1	1	1	1	1,510
Idelalisib	541	60.79	74.24	2	30	30	60	810
Female	254	57.49	60.31	3	30	30	60	416
Male	287	63.71	84.68	2	30	30	60	810
Olanzapine Extended Release	217	35.35	83.08	1	1	14	28	720
Female	133	36.46	72.81	1	1	14	28	584
Male	84	33.61	97.60	1	1	1	29	720
Panobinostat	188	42.54	50.35	6	21	28	42	488
Female	83	42.29	48.87	8	21	21	42	333
Male	105	42.73	51.72	6	21	28	42	488
Romiplostim	54,279	1.58	12.30	1	1	1	1	978
Female	28,085	1.56	10.75	1	1	1	1	672
Male	26,194	1.61	13.77	1	1	1	1	978
Teduglutide	659	70.78	104.15	1	30	30	60	1,142
Female	416	74.21	109.97	1	30	30	60	1,080
Male	243	64.90	93.26	2	30	30	60	1,142
Testosterone undecanoate	12,059	15.91	44.64	1	1	1	1	700
Female	51	19.65	46.98	1	1	1	1	200
Male	12,008	15.89	44.63	1	1	1	1	700
Vigabatrin	1,740	103.00	174.56	1	30	60	90	2,526
Female	779	103.76	168.34	1	30	60	90	1,850
Male	961	102.39	179.52	1	30	60	90	2,526

Table 7c: Descriptive statistics of second and subsequent exposure episode duration, in days, by age group (years)								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	13,433	61.56	103.81	1	30	30	60	3,041
00-17	64	55.89	80.04	1	30	30	60	600
18-24	779	51.74	73.05	1	30	30	60	1,156
25-40	2,559	55.63	92.34	1	30	30	60	1,676
41-64	8,571	63.35	110.06	1	30	30	60	3,041
65+	1,460	66.90	99.10	1	30	30	90	1,241
Alvimopan	0	-	-	-	-	-	-	-
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	0	-	-	-	-	-	-	-
41-64	0	-	-	-	-	-	-	-
65+	0	-	-	-	-	-	-	-
Denosumab	516,921	16.40	56.81	1	1	1	1	2,447
00-17	242	1.70	10.86	1	1	1	1	170
18-24	441	3.52	16.14	1	1	1	1	180
25-40	10,216	4.07	23.94	1	1	1	1	737
41-64	268,638	17.86	56.38	1	1	1	1	2,054
65+	237,384	15.31	58.25	1	1	1	1	2,447
Idelalisib	541	60.79	74.24	2	30	30	60	810
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	30	45.00	45.77	30	30	30	30	270
41-64	258	56.56	68.87	4	30	30	60	810
65+	253	66.98	81.52	2	30	30	60	690
Olanzapine Extended Release	217	35.35	83.08	1	1	14	28	720
00-17	7	1.00	0.00	1	1	1	1	1
18-24	74	27.80	90.81	1	1	1	28	720
25-40	47	40.00	61.23	1	1	28	56	292
41-64	79	46.72	93.51	1	2	14	56	584
65+	10	3.70	8.54	1	1	1	1	28
Panobinostat	188	42.54	50.35	6	21	28	42	488
00-17	1	8.00	-	8	8	8	8	8
18-24	0	-	-	-	-	-	-	-
25-40	0	-	-	-	-	-	-	-
41-64	145	44.47	54.72	6	21	28	42	488
65+	42	36.69	31.13	8	21	21	42	147
Romiplostim	54,279	1.58	12.30	1	1	1	1	978
00-17	1,224	6.14	44.95	1	1	1	1	978

Table 7c: Descriptive statistics of second and subsequent exposure episode duration, in days, by age group (years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
18-24	1,352	1.96	9.50	1	1	1	1	166	
25-40	5,070	1.41	5.04	1	1	1	1	140	
41-64	26,673	1.54	12.77	1	1	1	1	949	
65+	19,960	1.37	7.45	1	1	1	1	608	
Teduglutide	659	70.78	104.15	1	30	30	60	1,142	
00-17	25	79.72	74.16	23	30	60	90	332	
18-24	15	106.00	109.86	30	30	30	180	360	
25-40	88	54.36	73.03	5	30	30	60	630	
41-64	411	68.32	102.21	1	30	30	60	1,142	
65+	120	84.98	130.22	4	30	30	90	1,080	
Testosterone undecanoate	12,059	15.91	44.64	1	1	1	1	700	
00-17	4	1.00	0.00	1	1	1	1	1	
18-24	70	18.93	38.02	1	1	1	30	200	
25-40	1,631	11.01	31.38	1	1	1	1	560	
41-64	8,948	18.29	48.60	1	1	1	1	700	
65+	1,406	6.32	26.31	1	1	1	1	350	
Vigabatrin	1,740	103.00	174.56	1	30	60	90	2,526	
00-17	1,516	101.27	175.06	1	30	52	90	2,526	
18-24	111	109.62	180.95	17	30	60	120	1,350	
25-40	91	115.03	150.23	30	30	60	120	849	
41-64	22	138.91	204.39	28	30	60	150	968	
65+	0	-	-	-	-	-	-	-	



Table 8a: Distribution of all episode durations, by length categories, in days												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	18,694	100.0	13,101	70.1	3,913	20.9	1,382	7.4	214	1.1	84	0.4
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	673,916	100.0	606,876	90.1	24,276	3.6	40,570	6.0	1,877	0.3	317	0.0
Idelalisib	859	100.0	504	58.7	240	27.9	105	12.2	8	0.9	2	0.2
Olanzapine Extended Release	938	100.0	878	93.6	40	4.3	16	1.7	4	0.4	0	0.0
Panobinostat	343	100.0	220	64.1	97	28.3	25	7.3	1	0.3	0	0.0
Romiplostim	56,749	100.0	56,508	99.6	151	0.3	73	0.1	11	0.0	6	0.0
Teduglutide	864	100.0	499	57.8	239	27.7	107	12.4	15	1.7	4	0.5
Testosterone undecanoate	14,673	100.0	13,194	89.9	881	6.0	558	3.8	37	0.3	3	0.0
Vigabatrin	2,335	100.0	1,109	47.5	650	27.8	460	19.7	78	3.3	38	1.6

Table 8b: Distribution of all episode durations, by length categories, in days, by sex												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	18,694	100.0	13,101	100.0	3,913	100.0	1,382	100.0	214	100.0	84	100.0
Female	16,373	87.6	11,575	88.4	3,376	86.3	1,160	83.9	194	90.7	68	81.0
Male	2,321	12.4	1,526	11.6	537	13.7	222	16.1	20	9.3	16	19.0
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
Female	3	42.9	3	42.9	0	0.0	0	0.0	0	0.0	0	0.0
Male	4	57.1	4	57.1	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	673,916	100.0	606,876	100.0	24,276	100.0	40,570	100.0	1,877	100.0	317	100.0
Female	535,602	79.5	472,154	77.8	23,059	95.0	38,339	94.5	1,756	93.6	294	92.7
Male	138,314	20.5	134,722	22.2	1,217	5.0	2,231	5.5	121	6.4	23	7.3
Idelalisib	859	100.0	504	100.0	240	100.0	105	100.0	8	100.0	2	100.0
Female	392	45.6	239	47.4	100	41.7	50	47.6	3	37.5	0	0.0
Male	467	54.4	265	52.6	140	58.3	55	52.4	5	62.5	2	100.0
Olanzapine Extended Release	938	100.0	878	100.0	40	100.0	16	100.0	4	100.0	0	0.0
Female	478	51.0	442	50.3	22	55.0	12	75.0	2	50.0	0	0.0
Male	460	49.0	436	49.7	18	45.0	4	25.0	2	50.0	0	0.0
Panobinostat	343	100.0	220	100.0	97	100.0	25	100.0	1	100.0	0	0.0
Female	146	42.6	97	44.1	31	32.0	18	72.0	0	0.0	0	0.0
Male	197	57.4	123	55.9	66	68.0	7	28.0	1	100.0	0	0.0
Romiplostim	56,749	100.0	56,508	100.0	151	100.0	73	100.0	11	100.0	6	100.0
Female	29,382	51.8	29,264	51.8	77	51.0	33	45.2	6	54.5	2	33.3
Male	27,367	48.2	27,244	48.2	74	49.0	40	54.8	5	45.5	4	66.7
Teduglutide	864	100.0	499	100.0	239	100.0	107	100.0	15	100.0	4	100.0
Female	548	63.4	323	64.7	139	58.2	73	68.2	10	66.7	3	75.0
Male	316	36.6	176	35.3	100	41.8	34	31.8	5	33.3	1	25.0
Testosterone undecanoate	14,673	100.0	13,194	100.0	881	100.0	558	100.0	37	100.0	3	100.0
Female	73	0.5	66	0.5	2	0.2	5	0.9	0	0.0	0	0.0
Male	14,600	99.5	13,128	99.5	879	99.8	553	99.1	37	100.0	3	100.0
Vigabatrin	2,335	100.0	1,109	100.0	650	100.0	460	100.0	78	100.0	38	100.0
Female	1,047	44.8	490	44.2	291	44.8	213	46.3	34	43.6	19	50.0
Male	1,288	55.2	619	55.8	359	55.2	247	53.7	44	56.4	19	50.0

Table 8c: Distribution of all episode durations, by length categories, in days, by age group (years)												
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+	
	N	%	N	%	N	%	N	%	N	%	N	%
Alosetron	18,694	100.0	13,101	100.0	3,913	100.0	1,382	100.0	214	100.0	84	100.0
00-17	94	0.5	69	0.5	17	0.4	7	0.5	1	0.5	0	0.0
18-24	1,142	6.1	858	6.5	216	5.5	55	4.0	10	4.7	3	3.6
25-40	3,656	19.6	2,746	21.0	647	16.5	225	16.3	25	11.7	13	15.5
41-64	11,644	62.3	8,002	61.1	2,527	64.6	912	66.0	144	67.3	59	70.2
65+	2,158	11.5	1,426	10.9	506	12.9	183	13.2	34	15.9	9	10.7
Alvimopan	7	100.0	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	1	14.3	1	14.3	0	0.0	0	0.0	0	0.0	0	0.0
25-40	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
41-64	4	57.1	4	57.1	0	0.0	0	0.0	0	0.0	0	0.0
65+	2	28.6	2	28.6	0	0.0	0	0.0	0	0.0	0	0.0
Denosumab	673,916	100.0	606,876	100.0	24,276	100.0	40,570	100.0	1,877	100.0	317	100.0
00-17	279	0.0	278	0.0	0	0.0	1	0.0	0	0.0	0	0.0
18-24	559	0.1	542	0.1	13	0.1	4	0.0	0	0.0	0	0.0
25-40	11,988	1.8	11,695	1.9	124	0.5	165	0.4	3	0.2	1	0.3
41-64	348,778	51.8	309,325	51.0	16,460	67.8	21,936	54.1	946	50.4	111	35.0
65+	312,312	46.3	285,036	47.0	7,679	31.6	18,464	45.5	928	49.4	205	64.7
Idelalisib	859	100.0	504	100.0	240	100.0	105	100.0	8	100.0	2	100.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	34	4.0	26	5.2	5	2.1	3	2.9	0	0.0	0	0.0
41-64	409	47.6	232	46.0	130	54.2	44	41.9	2	25.0	1	50.0
65+	416	48.4	246	48.8	105	43.8	58	55.2	6	75.0	1	50.0
Olanzapine Extended Release	938	100.0	878	100.0	40	100.0	16	100.0	4	100.0	0	0.0
00-17	80	8.5	80	9.1	0	0.0	0	0.0	0	0.0	0	0.0
18-24	264	28.1	250	28.5	9	22.5	4	25.0	1	25.0	0	0.0
25-40	211	22.5	193	22.0	13	32.5	5	31.3	0	0.0	0	0.0
41-64	280	29.9	252	28.7	18	45.0	7	43.8	3	75.0	0	0.0
65+	103	11.0	103	11.7	0	0.0	0	0.0	0	0.0	0	0.0
Panobinostat	343	100.0	220	100.0	97	100.0	25	100.0	1	100.0	0	0.0
00-17	6	1.7	3	1.4	3	3.1	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	2	0.6	0	0.0	2	2.1	0	0.0	0	0.0	0	0.0
41-64	247	72.0	163	74.1	69	71.1	14	56.0	1	100.0	0	0.0
65+	88	25.7	54	24.5	23	23.7	11	44.0	0	0.0	0	0.0
Romiplostim	56,749	100.0	56,508	100.0	151	100.0	73	100.0	11	100.0	6	100.0



Table 8c: Distribution of all episode durations, by length categories, in days, by age group (years)													
Exposures	Total Episodes		1-30		31-90		91-365		366-730		731+		
	N	%	N	%	N	%	N	%	N	%	N	%	
00-17	1,303	2.3	1,269	2.2	17	11.3	13	17.8	3	27.3	1	16.7	
18-24	1,437	2.5	1,419	2.5	10	6.6	8	11.0	0	0.0	0	0.0	
25-40	5,345	9.4	5,325	9.4	16	10.6	4	5.5	0	0.0	0	0.0	
41-64	27,945	49.2	27,848	49.3	56	37.1	31	42.5	6	54.5	4	66.7	
65+	20,719	36.5	20,647	36.5	52	34.4	17	23.3	2	18.2	1	16.7	
Teduglutide	864	100.0	499	100.0	239	100.0	107	100.0	15	100.0	4	100.0	
00-17	36	4.2	17	3.4	13	5.4	6	5.6	0	0.0	0	0.0	
18-24	21	2.4	11	2.2	4	1.7	6	5.6	0	0.0	0	0.0	
25-40	112	13.0	69	13.8	34	14.2	7	6.5	2	13.3	0	0.0	
41-64	538	62.3	320	64.1	139	58.2	67	62.6	9	60.0	3	75.0	
65+	157	18.2	82	16.4	49	20.5	21	19.6	4	26.7	1	25.0	
Testosterone undecanoate	14,673	100.0	13,194	100.0	881	100.0	558	100.0	37	100.0	3	100.0	
00-17	6	0.0	6	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
18-24	85	0.6	71	0.5	9	1.0	5	0.9	0	0.0	0	0.0	
25-40	2,005	13.7	1,857	14.1	92	10.4	52	9.3	4	10.8	0	0.0	
41-64	10,930	74.5	9,681	73.4	740	84.0	473	84.8	33	89.2	3	100.0	
65+	1,647	11.2	1,579	12.0	40	4.5	28	5.0	0	0.0	0	0.0	
Vigabatrin	2,335	100.0	1,109	100.0	650	100.0	460	100.0	78	100.0	38	100.0	
00-17	2,032	87.0	978	88.2	562	86.5	393	85.4	65	83.3	34	89.5	
18-24	151	6.5	70	6.3	43	6.6	31	6.7	5	6.4	2	5.3	
25-40	114	4.9	44	4.0	38	5.8	25	5.4	6	7.7	1	2.6	
41-64	37	1.6	16	1.4	7	1.1	11	2.4	2	2.6	1	2.6	
65+	1	0.0	1	0.1	0	0.0	0	0.0	0	0.0	0	0.0	

Table 9a: Descriptive statistics of all exposure episode durations, in days								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	18,694	59.92	105.50	1	30	30	60	3,341
Alvimopan	7	3.00	2.31	1	1	3	5	7
Denosumab	673,916	18.52	61.35	1	1	1	1	2,447
Idelalisib	859	65.43	96.26	2	30	30	60	1,760
Olanzapine Extended Release	938	10.32	42.85	1	1	1	1	720
Panobinostat	343	41.38	45.67	5	21	28	42	488
Romiplostim	56,749	1.74	14.72	1	1	1	1	1,304
Teduglutide	864	71.69	103.31	1	30	30	60	1,142
Testosterone undecanoate	14,673	16.23	46.14	1	1	1	1	1,048
Vigabatrin	2,335	105.41	172.88	1	30	60	90	2,526

Table 9b: Descriptive statistics of all exposure episode durations, in days, by sex								
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	18,694	59.92	105.50	1	30	30	60	3,341
Female	16,373	59.08	104.71	1	30	30	60	3,341
Male	2,321	65.81	110.82	1	30	30	60	1,676
Alvimopan	7	3.00	2.31	1	1	3	5	7
Female	3	2.33	2.31	1	1	1	5	5
Male	4	3.50	2.52	1	2	3	5	7
Denosumab	673,916	18.52	61.35	1	1	1	1	2,447
Female	535,602	21.82	66.18	1	1	1	1	2,447
Male	138,314	5.74	34.26	1	1	1	1	2,001
Idelalisib	859	65.43	96.26	2	30	30	60	1,760
Female	392	62.06	70.18	3	30	30	60	630
Male	467	68.26	113.62	2	30	30	60	1,760
Olanzapine Extended Release	938	10.32	42.85	1	1	1	1	720
Female	478	11.79	41.73	1	1	1	1	584
Male	460	8.80	43.98	1	1	1	1	720
Panobinostat	343	41.38	45.67	5	21	28	42	488
Female	146	45.59	51.75	5	21	28	56	333
Male	197	38.26	40.43	6	21	28	42	488
Romiplostim	56,749	1.74	14.72	1	1	1	1	1,304
Female	29,382	1.70	14.17	1	1	1	1	1,304
Male	27,367	1.77	15.28	1	1	1	1	978
Teduglutide	864	71.69	103.31	1	30	30	60	1,142
Female	548	74.42	109.46	1	30	30	60	1,080
Male	316	66.95	91.66	2	30	30	60	1,142
Testosterone undecanoate	14,673	16.23	46.14	1	1	1	1	1,048
Female	73	15.16	40.09	1	1	1	1	200
Male	14,600	16.23	46.17	1	1	1	1	1,048
Vigabatrin	2,335	105.41	172.88	1	30	60	90	2,526
Female	1,047	106.49	167.69	1	30	60	108	1,850
Male	1,288	104.53	177.06	1	30	60	90	2,526

Table 9c: Descriptive statistics of all exposure episode durations, in days, by age group (years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
Alosetron	18,694	59.92	105.50	1	30	30	60	3,341	
00-17	94	52.38	73.17	1	30	30	44	600	
18-24	1,142	50.11	74.60	1	30	30	30	1,156	
25-40	3,656	52.41	86.94	1	30	30	30	1,676	
41-64	11,644	62.54	114.41	1	30	30	60	3,341	
65+	2,158	63.99	98.10	1	30	30	60	1,620	
Alvimopan	7	3.00	2.31	1	1	3	5	7	
00-17	0	-	-	-	-	-	-	-	
18-24	1	5.00	-	5	5	5	5	5	
25-40	0	-	-	-	-	-	-	-	
41-64	4	3.00	2.83	1	1	2	5	7	
65+	2	2.00	1.41	1	1	2	3	3	
Denosumab	673,916	18.52	61.35	1	1	1	1	2,447	
00-17	279	1.81	10.38	1	1	1	1	170	
18-24	559	4.28	18.26	1	1	1	1	180	
25-40	11,988	4.94	27.00	1	1	1	1	737	
41-64	348,778	19.90	60.29	1	1	1	1	2,054	
65+	312,312	17.54	63.43	1	1	1	1	2,447	
Idelalisib	859	65.43	96.26	2	30	30	60	1,760	
00-17	0	-	-	-	-	-	-	-	
18-24	0	-	-	-	-	-	-	-	
25-40	34	54.24	62.25	14	30	30	30	270	
41-64	409	59.79	69.00	2	30	30	60	810	
65+	416	71.88	118.67	2	30	30	60	1,760	
Olanzapine Extended Release	938	10.32	42.85	1	1	1	1	720	
00-17	80	1.38	3.02	1	1	1	1	28	
18-24	264	10.26	49.63	1	1	1	1	720	
25-40	211	10.93	33.22	1	1	1	1	292	
41-64	280	15.64	54.10	1	1	1	4	584	
65+	103	1.75	3.95	1	1	1	1	28	
Panobinostat	343	41.38	45.67	5	21	28	42	488	
00-17	6	38.50	28.37	8	21	35	42	90	
18-24	0	-	-	-	-	-	-	-	
25-40	2	52.50	14.85	42	42	53	63	63	
41-64	247	40.70	46.92	5	21	28	42	488	
65+	88	43.23	43.79	8	21	28	49	304	
Romiplostim	56,749	1.74	14.72	1	1	1	1	1,304	
00-17	1,303	7.05	46.66	1	1	1	1	978	

Table 9c: Descriptive statistics of all exposure episode durations, in days, by age group (years)									
Exposures	Total Episodes	Mean	STD	Min	Q1	Median	Q3	Max	
18-24	1,437	2.39	12.98	1	1	1	1	252	
25-40	5,345	1.45	5.36	1	1	1	1	140	
41-64	27,945	1.68	15.83	1	1	1	1	1,304	
65+	20,719	1.50	9.87	1	1	1	1	840	
Teduglutide	864	71.69	103.31	1	30	30	60	1,142	
00-17	36	70.14	65.11	23	30	60	88	332	
18-24	21	88.43	96.83	7	30	30	120	360	
25-40	112	58.55	75.46	5	30	30	60	630	
41-64	538	72.06	106.64	1	30	30	60	1,142	
65+	157	77.93	116.16	1	30	30	90	1,080	
Testosterone undecanoate	14,673	16.23	46.14	1	1	1	1	1,048	
00-17	6	1.00	0.00	1	1	1	1	1	
18-24	85	20.82	40.98	1	1	1	30	200	
25-40	2,005	12.03	33.53	1	1	1	1	560	
41-64	10,930	18.42	50.10	1	1	1	28	1,048	
65+	1,647	6.60	26.66	1	1	1	1	350	
Vigabatrin	2,335	105.41	172.88	1	30	60	90	2,526	
00-17	2,032	104.78	174.92	1	30	58	90	2,526	
18-24	151	105.63	166.20	14	30	60	120	1,350	
25-40	114	110.28	143.85	16	30	60	120	849	
41-64	37	126.32	175.68	28	30	60	150	968	
65+	1	30.00	-	30	30	30	30	30	

Table 10a: Distribution of days supplied per dispensing, by length categories										
Exposures	Total Dispensings		1-30		31-60		61-90		91+	
	N	%	N	%	N	%	N	%	N	%
Alosetron	31,092	100.0	27,157	87.3	465	1.5	3,441	11.1	29	0.1
Alvimopan	9	100.0	9	100.0	0	0.0	0	0.0	0	0.0
Denosumab	697,342	100.0	619,261	88.8	3,709	0.5	21,880	3.1	52,492	7.5
Idelalisib	1,920	100.0	1,907	99.3	13	0.7	0	0.0	0	0.0
Olanzapine Extended Release	1,257	100.0	1,255	99.8	1	0.1	0	0.0	1	0.1
Panobinostat	617	100.0	601	97.4	11	1.8	5	0.8	0	0.0
Romiplostim	57,990	100.0	57,865	99.8	30	0.1	95	0.2	0	0.0
Teduglutide	2,111	100.0	2,096	99.3	13	0.6	2	0.1	0	0.0
Testosterone undecanoate	16,258	100.0	13,916	85.6	154	0.9	2,186	13.4	2	0.0
Vigabatrin	8,273	100.0	8,200	99.1	46	0.6	23	0.3	4	0.0

Table 10b: Distribution of days supplied per dispensing, by length categories, by sex										
Exposures	Total Dispensings		1-30		31-60		61-90		91+	
	N	%	N	%	N	%	N	%	N	%
Alosetron	31,092	100.0	27,157	100.0	465	100.0	3,441	100.0	29	100.0
Female	26,972	86.7	23,647	87.1	369	79.4	2,928	85.1	28	96.6
Male	4,120	13.3	3,510	12.9	96	20.6	513	14.9	1	3.4
Alvimopan	9	100.0	9	100.0	0	0.0	0	0.0	0	0.0
Female	3	33.3	3	33.3	0	0.0	0	0.0	0	0.0
Male	6	66.7	6	66.7	0	0.0	0	0.0	0	0.0
Denosumab	697,342	100.0	619,261	100.0	3,709	100.0	21,880	100.0	52,492	100.0
Female	557,655	80.0	483,821	78.1	3,514	94.7	20,787	95.0	49,533	94.4
Male	139,687	20.0	135,440	21.9	195	5.3	1,093	5.0	2,959	5.6
Idelalisib	1,920	100.0	1,907	100.0	13	100.0	0	0.0	0	0.0
Female	826	43.0	823	43.2	3	23.1	0	0.0	0	0.0
Male	1,094	57.0	1,084	56.8	10	76.9	0	0.0	0	0.0
Olanzapine Extended Release	1,257	100.0	1,255	100.0	1	100.0	0	0.0	1	100.0
Female	695	55.3	695	55.4	0	0.0	0	0.0	0	0.0
Male	562	44.7	560	44.6	1	100.0	0	0.0	1	100.0
Panobinostat	617	100.0	601	100.0	11	100.0	5	100.0	0	0.0
Female	287	46.5	277	46.1	5	45.5	5	100.0	0	0.0
Male	330	53.5	324	53.9	6	54.5	0	0.0	0	0.0
Romiplostim	57,990	100.0	57,865	100.0	30	100.0	95	100.0	0	0.0
Female	30,028	51.8	29,988	51.8	9	30.0	31	32.6	0	0.0
Male	27,962	48.2	27,877	48.2	21	70.0	64	67.4	0	0.0
Teduglutide	2,111	100.0	2,096	100.0	13	100.0	2	100.0	0	0.0
Female	1,396	66.1	1,390	66.3	4	30.8	2	100.0	0	0.0
Male	715	33.9	706	33.7	9	69.2	0	0.0	0	0.0
Testosterone undecanoate	16,258	100.0	13,916	100.0	154	100.0	2,186	100.0	2	100.0
Female	81	0.5	69	0.5	0	0.0	12	0.5	0	0.0
Male	16,177	99.5	13,847	99.5	154	100.0	2,174	99.5	2	100.0
Vigabatrin	8,273	100.0	8,200	100.0	46	100.0	23	100.0	4	100.0
Female	3,749	45.3	3,721	45.4	15	32.6	10	43.5	3	75.0
Male	4,524	54.7	4,479	54.6	31	67.4	13	56.5	1	25.0

Table 10c: Distribution of days supplied per dispensing, by length categories, by age group (years)										
Exposures	Total Dispensings		1-30		31-60		61-90		91+	
	N	%	N	%	N	%	N	%	N	%
Alosetron	31,092	100.0	27,157	100.0	465	100.0	3,441	100.0	29	100.0
00-17	148	0.5	129	0.5	14	3.0	5	0.1	0	0.0
18-24	1,742	5.6	1,621	6.0	18	3.9	103	3.0	0	0.0
25-40	5,676	18.3	5,176	19.1	61	13.1	436	12.7	3	10.3
41-64	19,927	64.1	17,275	63.6	277	59.6	2,353	68.4	22	75.9
65+	3,599	11.6	2,956	10.9	95	20.4	544	15.8	4	13.8
Alvimopan	9	100.0	9	100.0	0	0.0	0	0.0	0	0.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	1	11.1	1	11.1	0	0.0	0	0.0	0	0.0
25-40	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
41-64	4	44.4	4	44.4	0	0.0	0	0.0	0	0.0
65+	4	44.4	4	44.4	0	0.0	0	0.0	0	0.0
Denosumab	697,342	100.0	619,261	100.0	3,709	100.0	21,880	100.0	52,492	100.0
00-17	280	0.0	278	0.0	1	0.0	0	0.0	1	0.0
18-24	566	0.1	552	0.1	2	0.1	8	0.0	4	0.0
25-40	12,078	1.7	11,752	1.9	33	0.9	98	0.4	195	0.4
41-64	361,757	51.9	316,758	51.2	2,167	58.4	15,013	68.6	27,819	53.0
65+	322,661	46.3	289,921	46.8	1,506	40.6	6,761	30.9	24,473	46.6
Idelalisib	1,920	100.0	1,907	100.0	13	100.0	0	0.0	0	0.0
00-17	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	62	3.2	62	3.3	0	0.0	0	0.0	0	0.0
41-64	839	43.7	835	43.8	4	30.8	0	0.0	0	0.0
65+	1,019	53.1	1,010	53.0	9	69.2	0	0.0	0	0.0
Olanzapine Extended Release	1,257	100.0	1,255	100.0	1	100.0	0	0.0	1	100.0
00-17	83	6.6	83	6.6	0	0.0	0	0.0	0	0.0
18-24	327	26.0	325	25.9	1	100.0	0	0.0	1	100.0
25-40	288	22.9	288	22.9	0	0.0	0	0.0	0	0.0
41-64	446	35.5	446	35.5	0	0.0	0	0.0	0	0.0
65+	113	9.0	113	9.0	0	0.0	0	0.0	0	0.0
Panobinostat	617	100.0	601	100.0	11	100.0	5	100.0	0	0.0
00-17	10	1.6	10	1.7	0	0.0	0	0.0	0	0.0
18-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-40	5	0.8	5	0.8	0	0.0	0	0.0	0	0.0
41-64	439	71.2	431	71.7	7	63.6	1	20.0	0	0.0
65+	163	26.4	155	25.8	4	36.4	4	80.0	0	0.0
Romiplostim	57,990	100.0	57,865	100.0	30	100.0	95	100.0	0	0.0

Exposures	Total Dispensings		1-30		31-60		61-90		91+	
	N	%	N	%	N	%	N	%	N	%
00-17	1,526	2.6	1,518	2.6	1	3.3	7	7.4	0	0.0
18-24	1,490	2.6	1,485	2.6	0	0.0	5	5.3	0	0.0
25-40	5,394	9.3	5,391	9.3	1	3.3	2	2.1	0	0.0
41-64	28,471	49.1	28,384	49.1	10	33.3	77	81.1	0	0.0
65+	21,109	36.4	21,087	36.4	18	60.0	4	4.2	0	0.0
Teduglutide	2,111	100.0	2,096	100.0	13	100.0	2	100.0	0	0.0
00-17	87	4.1	87	4.2	0	0.0	0	0.0	0	0.0
18-24	63	3.0	63	3.0	0	0.0	0	0.0	0	0.0
25-40	223	10.6	222	10.6	1	7.7	0	0.0	0	0.0
41-64	1,323	62.7	1,311	62.5	12	92.3	0	0.0	0	0.0
65+	415	19.7	413	19.7	0	0.0	2	100.0	0	0.0
Testosterone undecanoate	16,258	100.0	13,916	100.0	154	100.0	2,186	100.0	2	100.0
00-17	6	0.0	6	0.0	0	0.0	0	0.0	0	0.0
18-24	97	0.6	79	0.6	1	0.6	17	0.8	0	0.0
25-40	2,144	13.2	1,952	14.0	14	9.1	176	8.1	2	100.0
41-64	12,294	75.6	10,264	73.8	134	87.0	1,896	86.7	0	0.0
65+	1,717	10.6	1,615	11.6	5	3.2	97	4.4	0	0.0
Vigabatrin	8,273	100.0	8,200	100.0	46	100.0	23	100.0	4	100.0
00-17	7,152	86.4	7,082	86.4	43	93.5	23	100.0	4	100.0
18-24	542	6.6	542	6.6	0	0.0	0	0.0	0	0.0
25-40	420	5.1	417	5.1	3	6.5	0	0.0	0	0.0
41-64	158	1.9	158	1.9	0	0.0	0	0.0	0	0.0
65+	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0

Table 11a: Descriptive statistics of days supplied per dispensing								
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	31,092	36.03	19.81	1	30	30	30	180
Alvimopan	9	2.33	2.24	1	1	1	3	7
Denosumab	697,342	17.91	47.53	1	1	1	1	1,440
Idelalisib	1,920	29.27	4.25	1	30	30	30	60
Olanzapine Extended Release	1,257	7.71	13.99	1	1	1	14	360
Panobinostat	617	23.00	7.23	4	21	21	28	90
Romiplostim	57,990	1.70	5.11	1	1	1	1	90
Teduglutide	2,111	29.34	5.26	1	30	30	30	90
Testosterone undecanoate	16,258	14.66	24.19	1	1	1	28	170
Vigabatrin	8,273	29.75	5.73	1	30	30	30	210

Table 11b: Descriptive statistics of days supplied per dispensing, by sex									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
Alosetron	31,092	36.03	19.81	1	30	30	30	180	
Female	26,972	35.87	19.66	1	30	30	30	180	
Male	4,120	37.08	20.70	1	30	30	30	180	
Alvimopan	9	2.33	2.24	1	1	1	3	7	
Female	3	2.33	2.31	1	1	1	5	5	
Male	6	2.33	2.42	1	1	1	3	7	
Denosumab	697,342	17.91	47.53	1	1	1	1	1,440	
Female	557,655	20.98	50.99	1	1	1	1	1,440	
Male	139,687	5.68	26.62	1	1	1	1	1,152	
Idelalisib	1,920	29.27	4.25	1	30	30	30	60	
Female	826	29.45	3.84	1	30	30	30	60	
Male	1,094	29.14	4.53	2	30	30	30	60	
Olanzapine Extended Release	1,257	7.71	13.99	1	1	1	14	360	
Female	695	8.11	9.47	1	1	1	14	30	
Male	562	7.20	18.08	1	1	1	14	360	
Panobinostat	617	23.00	7.23	4	21	21	28	90	
Female	287	23.19	9.01	4	21	21	28	90	
Male	330	22.84	5.22	5	21	21	28	56	
Romiplostim	57,990	1.70	5.11	1	1	1	1	90	
Female	30,028	1.67	4.70	1	1	1	1	84	
Male	27,962	1.74	5.52	1	1	1	1	90	
Teduglutide	2,111	29.34	5.26	1	30	30	30	90	
Female	1,396	29.21	5.29	1	30	30	30	90	
Male	715	29.59	5.21	2	30	30	30	60	
Testosterone undecanoate	16,258	14.66	24.19	1	1	1	28	170	
Female	81	13.68	24.94	1	1	1	1	70	
Male	16,177	14.66	24.19	1	1	1	28	170	
Vigabatrin	8,273	29.75	5.73	1	30	30	30	210	
Female	3,749	29.74	6.12	1	30	30	30	210	
Male	4,524	29.76	5.38	1	30	30	30	150	

Table 11c: Descriptive statistics of days supplied per dispensing, by age group (years)									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
Alosetron	31,092	36.03	19.81	1	30	30	30	180	
00-17	148	33.27	14.97	1	30	30	30	90	
18-24	1,742	32.85	14.98	1	30	30	30	90	
25-40	5,676	33.76	17.17	1	30	30	30	180	
41-64	19,927	36.55	20.19	1	30	30	30	180	
65+	3,599	38.37	23.03	1	30	30	30	180	
Alvimopan	9	2.33	2.24	1	1	1	3	7	
00-17	0	-	-	-	-	-	-	-	
18-24	1	5.00	-	5	5	5	5	5	
25-40	0	-	-	-	-	-	-	-	
41-64	4	3.00	2.83	1	1	2	5	7	
65+	4	1.00	0.00	1	1	1	1	1	
Denosumab	697,342	17.91	47.53	1	1	1	1	1,440	
00-17	280	1.80	7.80	1	1	1	1	112	
18-24	566	4.23	17.53	1	1	1	1	180	
25-40	12,078	4.91	23.38	1	1	1	1	210	
41-64	361,757	19.20	47.74	1	1	1	1	900	
65+	322,661	16.99	47.92	1	1	1	1	1,440	
Idelalisib	1,920	29.27	4.25	1	30	30	30	60	
00-17	0	-	-	-	-	-	-	-	
18-24	0	-	-	-	-	-	-	-	
25-40	62	29.74	2.03	14	30	30	30	30	
41-64	839	29.15	4.70	2	30	30	30	60	
65+	1,019	29.35	3.95	1	30	30	30	60	
Olanzapine Extended Release	1,257	7.71	13.99	1	1	1	14	360	
00-17	83	1.33	2.96	1	1	1	1	28	
18-24	327	8.29	22.27	1	1	1	14	360	
25-40	288	8.01	10.16	1	1	1	14	30	
41-64	446	9.82	9.77	1	1	14	14	30	
65+	113	1.59	3.76	1	1	1	1	28	
Panobinostat	617	23.00	7.23	4	21	21	28	90	
00-17	10	23.10	8.02	8	21	25	30	30	
18-24	0	-	-	-	-	-	-	-	
25-40	5	21.00	0.00	21	21	21	21	21	
41-64	439	22.90	6.13	4	21	21	28	90	
65+	163	23.34	9.67	6	21	21	21	90	
Romiplostim	57,990	1.70	5.11	1	1	1	1	90	
00-17	1,526	6.03	11.45	1	1	1	1	84	

Table 11c: Descriptive statistics of days supplied per dispensing, by age group (years)									
Exposures	Total Dispensings	Mean	STD	Min	Q1	Median	Q3	Max	
18-24	1,490	2.31	6.98	1	1	1	1	84	
25-40	5,394	1.44	3.68	1	1	1	1	84	
41-64	28,471	1.66	5.47	1	1	1	1	90	
65+	21,109	1.48	3.69	1	1	1	1	84	
Teduglutide	2,111	29.34	5.26	1	30	30	30	90	
00-17	87	29.02	3.69	2	30	30	30	30	
18-24	63	29.48	3.14	7	30	30	30	30	
25-40	223	29.41	4.25	4	30	30	30	60	
41-64	1,323	29.30	5.44	1	30	30	30	60	
65+	415	29.48	5.71	1	30	30	30	90	
Testosterone undecanoate	16,258	14.66	24.19	1	1	1	28	170	
00-17	6	1.00	0.00	1	1	1	1	1	
18-24	97	18.28	26.42	1	1	1	30	70	
25-40	2,144	11.26	20.83	1	1	1	1	170	
41-64	12,294	16.39	25.27	1	1	1	30	90	
65+	1,717	6.33	16.80	1	1	1	1	70	
Vigabatrin	8,273	29.75	5.73	1	30	30	30	210	
00-17	7,152	29.77	6.03	1	30	30	30	210	
18-24	542	29.43	3.05	1	30	30	30	30	
25-40	420	29.93	3.45	1	30	30	30	60	
41-64	158	29.58	2.42	8	30	30	30	30	
65+	1	30.00	-	30	30	30	30	30	

Table 12a: Descriptive statistics of the length of the first gap between treatment episodes, in days								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	2,665	70.32	184.56	1	5	18	52	2,689
Alvimopan	0	-	-	-	-	-	-	-
Denosumab	109,685	169.76	157.02	1	55	181	194	2,993
Idelalisib	186	15.92	33.68	1	2	5	23	410
Olanzapine Extended Release	72	130.14	199.84	1	8	30	182	777
Panobinostat	86	26.85	90.50	1	4	8	18	750
Romiplostim	2,112	16.62	68.75	1	6	6	9	1,720
Teduglutide	133	33.99	124.13	1	2	7	20	1,292
Testosterone undecanoate	2,098	39.36	47.16	1	25	28	39	650
Vigabatrin	379	27.95	136.18	1	3	6	15	2,315

Table 12b: Descriptive statistics of the length of the first gap between treatment episodes, in days, by sex								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	2,665	70.32	184.56	1	5	18	52	2,689
Female	2,340	72.72	188.42	1	5	19	54	2,689
Male	325	53.08	153.11	1	5	14	39	1,371
Alvimopan	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Denosumab	109,685	169.76	157.02	1	55	181	194	2,993
Female	93,018	181.31	159.59	1	119	183	195	2,993
Male	16,667	105.31	123.42	1	27	41	182	2,686
Idelalisib	186	15.92	33.68	1	2	5	23	410
Female	82	19.65	47.10	1	3	6	23	410
Male	104	12.98	16.54	1	2	5	22	95
Olanzapine Extended Release	72	130.14	199.84	1	8	30	182	777
Female	34	114.47	206.90	1	8	28	75	777
Male	38	144.16	195.01	1	8	37	229	662
Panobinostat	86	26.85	90.50	1	4	8	18	750
Female	35	46.91	139.70	1	3	9	15	750
Male	51	13.08	13.29	1	4	7	21	60
Romiplostim	2,112	16.62	68.75	1	6	6	9	1,720
Female	1,106	18.33	74.75	1	6	6	9	1,353
Male	1,006	14.73	61.46	1	6	6	9	1,720
Teduglutide	133	33.99	124.13	1	2	7	20	1,292
Female	87	44.05	151.62	1	3	9	24	1,292
Male	46	14.98	26.46	1	2	6	18	151
Testosterone undecanoate	2,098	39.36	47.16	1	25	28	39	650
Female	10	23.10	15.62	1	12	27	32	46
Male	2,088	39.44	47.24	1	25	28	39	650
Vigabatrin	379	27.95	136.18	1	3	6	15	2,315
Female	183	22.69	77.31	1	3	5	17	848
Male	196	32.87	174.13	1	3	6	15	2,315

Table 12c: Descriptive statistics of the length of the first gap between treatment episodes, in days, by age group (years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	2,665	70.32	184.56	1	5	18	52	2,689
00-17	17	77.18	145.37	4	10	29	82	620
18-24	169	72.64	202.98	1	5	19	41	1,825
25-40	532	59.10	167.77	1	5	17	45	2,462
41-64	1,625	73.41	194.72	1	5	18	51	2,689
65+	322	71.73	146.44	1	6	23	67	1,203
Alvimopan	0	-	-	-	-	-	-	-
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	0	-	-	-	-	-	-	-
41-64	0	-	-	-	-	-	-	-
65+	0	-	-	-	-	-	-	-
Denosumab	109,685	169.76	157.02	1	55	181	194	2,993
00-17	27	32.96	52.30	5	6	15	27	225
18-24	78	76.81	89.20	1	8	31	178	380
25-40	1,331	101.88	138.89	1	27	41	181	1,821
41-64	56,116	161.72	152.45	1	41	181	193	2,823
65+	52,133	180.35	161.34	1	105	183	195	2,993
Idelalisib	186	15.92	33.68	1	2	5	23	410
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	2	25.50	2.12	24	24	26	27	27
41-64	93	16.96	43.47	1	3	6	23	410
65+	91	14.65	19.90	1	2	5	22	95
Olanzapine Extended Release	72	130.14	199.84	1	8	30	182	777
00-17	7	330.14	258.72	28	75	384	542	681
18-24	26	122.31	173.05	1	7	26	201	662
25-40	13	71.46	92.54	1	6	28	75	236
41-64	19	134.79	255.65	2	8	27	72	777
65+	7	55.57	82.01	1	3	15	83	229
Panobinostat	86	26.85	90.50	1	4	8	18	750
00-17	1	1.00	-	1	1	1	1	1
18-24	0	-	-	-	-	-	-	-
25-40	0	-	-	-	-	-	-	-
41-64	62	32.71	105.82	1	4	9	21	750
65+	23	12.17	15.50	2	3	6	15	60
Romiplostim	2,112	16.62	68.75	1	6	6	9	1,720
00-17	62	15.35	27.54	1	6	6	12	173

Table 12c: Descriptive statistics of the length of the first gap between treatment episodes, in days, by age group (years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
18-24	70	18.77	71.70	3	6	6	12	604
25-40	238	14.97	45.64	1	6	6	13	679
41-64	1,069	16.35	60.79	1	6	6	9	1,252
65+	673	17.52	87.41	1	6	6	8	1,720
Teduglutide	133	33.99	124.13	1	2	7	20	1,292
00-17	9	18.33	26.41	2	3	6	20	85
18-24	1	14.00	-	14	14	14	14	14
25-40	17	31.65	77.97	1	3	6	19	327
41-64	84	41.94	151.60	1	3	8	22	1,292
65+	22	12.77	16.49	1	2	6	18	64
Testosterone undecanoate	2,098	39.36	47.16	1	25	28	39	650
00-17	2	50.50	26.16	32	32	51	69	69
18-24	10	19.20	10.67	1	8	25	28	30
25-40	286	38.99	44.96	1	23	28	41	524
41-64	1,590	39.02	47.46	1	23	28	39	650
65+	210	43.36	48.85	1	27	28	42	572
Vigabatrin	379	27.95	136.18	1	3	6	15	2,315
00-17	329	30.47	145.91	1	3	6	17	2,315
18-24	26	8.77	12.52	1	3	5	11	63
25-40	16	14.50	19.62	2	5	9	13	80
41-64	8	13.88	12.16	2	7	11	17	41
65+	0	-	-	-	-	-	-	-

Table 13a: Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	10,768	45.87	100.64	1	6	19	43	1,992
Alvimopan	0	-	-	-	-	-	-	-
Denosumab	407,236	117.49	128.20	1	27	61	185	2,694
Idelalisib	355	15.24	37.06	1	3	5	13	392
Olanzapine Extended Release	145	23.86	59.03	1	3	7	20	462
Panobinostat	102	22.83	88.80	1	4	7	14	646
Romiplostim	52,167	11.71	39.39	1	6	6	9	2,344
Teduglutide	526	20.88	77.16	1	3	6	16	1,061
Testosterone undecanoate	9,961	67.00	63.20	1	44	69	73	1,525
Vigabatrin	1,361	18.06	79.63	1	2	5	12	1,601

Table 13b: Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by sex								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	10,768	45.87	100.64	1	6	19	43	1,992
Female	9,419	47.30	103.22	1	6	19	45	1,992
Male	1,349	35.88	79.64	1	5	14	34	1,345
Alvimopan	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Denosumab	407,236	117.49	128.20	1	27	61	185	2,694
Female	308,170	135.82	134.93	1	28	162	188	2,694
Male	99,066	60.45	81.41	1	27	30	47	2,414
Idelalisib	355	15.24	37.06	1	3	5	13	392
Female	172	14.01	26.80	1	3	5	13	251
Male	183	16.39	44.65	1	3	6	14	392
Olanzapine Extended Release	145	23.86	59.03	1	3	7	20	462
Female	99	22.62	54.33	1	3	6	18	350
Male	46	26.54	68.65	1	3	11	22	462
Panobinostat	102	22.83	88.80	1	4	7	14	646
Female	48	23.63	91.07	1	4	7	14	635
Male	54	22.13	87.59	1	3	6	15	646
Romiplostim	52,167	11.71	39.39	1	6	6	9	2,344
Female	26,979	11.87	39.32	1	6	6	11	1,644
Male	25,188	11.53	39.45	1	6	6	8	2,344
Teduglutide	526	20.88	77.16	1	3	6	16	1,061
Female	329	27.28	96.09	1	3	7	22	1,061
Male	197	10.21	17.65	1	3	5	11	170
Testosterone undecanoate	9,961	67.00	63.20	1	44	69	73	1,525
Female	41	61.95	26.52	1	55	65	69	118
Male	9,920	67.02	63.30	1	44	69	73	1,525
Vigabatrin	1,361	18.06	79.63	1	2	5	12	1,601
Female	596	19.18	73.26	1	2	5	13	1,049
Male	765	17.19	84.30	1	2	5	12	1,601

Table 13c: Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by age group (years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	10,768	45.87	100.64	1	6	19	43	1,992
00-17	47	70.89	156.06	1	2	12	79	829
18-24	610	36.52	74.54	1	5	13	35	999
25-40	2,027	43.17	88.32	1	6	20	43	1,316
41-64	6,946	45.44	100.35	1	5	18	42	1,829
65+	1,138	57.29	127.79	1	7	24	57	1,992
Alvimopan	0	-	-	-	-	-	-	-
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	0	-	-	-	-	-	-	-
41-64	0	-	-	-	-	-	-	-
65+	0	-	-	-	-	-	-	-
Denosumab	407,236	117.49	128.20	1	27	61	185	2,694
00-17	215	38.48	54.04	5	27	27	34	516
18-24	363	60.30	78.06	2	27	28	48	732
25-40	8,885	55.68	73.25	1	27	29	45	1,998
41-64	212,522	108.99	122.80	1	27	47	183	2,671
65+	185,251	130.40	134.57	1	27	139	188	2,694
Idelalisib	355	15.24	37.06	1	3	5	13	392
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	28	13.89	14.16	1	4	7	19	48
41-64	165	14.05	34.26	1	2	6	13	392
65+	162	16.69	42.27	1	3	5	13	316
Olanzapine Extended Release	145	23.86	59.03	1	3	7	20	462
00-17	0	-	-	-	-	-	-	-
18-24	48	19.81	65.92	1	3	7	15	462
25-40	34	28.79	60.86	1	3	11	29	350
41-64	60	25.40	54.02	1	3	8	18	328
65+	3	2.00	1.00	1	1	2	3	3
Panobinostat	102	22.83	88.80	1	4	7	14	646
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	0	-	-	-	-	-	-	-
41-64	83	17.98	71.20	1	4	6	14	646
65+	19	44.05	143.42	1	4	9	18	635
Romiplostim	52,167	11.71	39.39	1	6	6	9	2,344
00-17	1,162	11.06	32.78	1	6	6	9	650



Table 13c: Descriptive statistics of the length of second and subsequent gaps between treatment episodes, in days, by age group (years)									
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max	
18-24	1,282	10.84	26.60	1	6	6	9	750	
25-40	4,832	12.17	43.86	1	6	6	10	1,800	
41-64	25,604	12.07	42.06	1	6	6	9	2,344	
65+	19,287	11.20	35.39	1	6	6	9	1,644	
Teduglutide	526	20.88	77.16	1	3	6	16	1,061	
00-17	16	3.81	3.08	1	1	3	6	11	
18-24	14	18.29	26.91	1	4	11	16	106	
25-40	71	20.59	39.61	1	4	6	19	202	
41-64	327	24.45	93.42	1	3	6	18	1,061	
65+	98	12.35	38.70	1	2	5	13	380	
Testosterone undecanoate	9,961	67.00	63.20	1	44	69	73	1,525	
00-17	2	44.00	11.31	36	36	44	52	52	
18-24	60	27.80	25.98	1	13	13	34	109	
25-40	1,345	63.00	59.84	1	38	68	71	1,525	
41-64	7,358	66.27	65.31	1	41	69	73	1,525	
65+	1,196	77.97	52.36	1	69	69	76	846	
Vigabatrin	1,361	18.06	79.63	1	2	5	12	1,601	
00-17	1,187	19.12	84.13	1	2	5	13	1,601	
18-24	85	12.32	47.58	1	2	4	8	438	
25-40	75	10.43	19.21	1	2	5	10	139	
41-64	14	4.14	4.69	1	1	3	5	19	
65+	0	-	-	-	-	-	-	-	

Table 14a: Descriptive statistics of the length of all gaps between treatment episodes, in days								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	13,433	50.72	122.35	1	5	19	44	2,689
Alvimopan	0	-	-	-	-	-	-	-
Denosumab	516,921	128.58	136.51	1	27	105	187	2,993
Idelalisib	541	15.47	35.91	1	3	5	16	410
Olanzapine Extended Release	217	59.12	134.04	1	3	12	32	777
Panobinostat	188	24.67	89.36	1	4	7	15	750
Romiplostim	54,279	11.90	40.93	1	6	6	9	2,344
Teduglutide	659	23.53	88.71	1	2	6	17	1,292
Testosterone undecanoate	12,059	62.19	61.61	1	32	69	71	1,525
Vigabatrin	1,740	20.22	94.91	1	3	5	13	2,315

Table 14b: Descriptive statistics of the length of all gaps between treatment episodes, in days, by sex								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	13,433	50.72	122.35	1	5	19	44	2,689
Female	11,759	52.36	125.30	1	6	19	46	2,689
Male	1,674	39.22	98.47	1	5	14	34	1,371
Alvimopan	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Denosumab	516,921	128.58	136.51	1	27	105	187	2,993
Female	401,188	146.37	142.33	1	30	180	188	2,993
Male	115,733	66.91	90.09	1	27	30	55	2,686
Idelalisib	541	15.47	35.91	1	3	5	16	410
Female	254	15.83	34.68	1	3	5	16	410
Male	287	15.16	37.01	1	2	5	15	392
Olanzapine Extended Release	217	59.12	134.04	1	3	12	32	777
Female	133	46.10	120.46	1	3	8	28	777
Male	84	79.75	151.58	1	4	15	57	662
Panobinostat	188	24.67	89.36	1	4	7	15	750
Female	83	33.45	113.93	1	4	7	14	750
Male	105	17.73	63.36	1	4	7	18	646
Romiplostim	54,279	11.90	40.93	1	6	6	9	2,344
Female	28,085	12.13	41.31	1	6	6	11	1,644
Male	26,194	11.65	40.52	1	6	6	8	2,344
Teduglutide	659	23.53	88.71	1	2	6	17	1,292
Female	416	30.78	110.04	1	3	7	23	1,292
Male	243	11.11	19.65	1	2	6	12	170
Testosterone undecanoate	12,059	62.19	61.61	1	32	69	71	1,525
Female	51	54.33	29.14	1	32	62	69	118
Male	12,008	62.22	61.71	1	32	69	71	1,525
Vigabatrin	1,740	20.22	94.91	1	3	5	13	2,315
Female	779	20.01	74.19	1	3	5	13	1,049
Male	961	20.39	108.88	1	2	5	12	2,315

Table 14c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years)								
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max
Alosetron	13,433	50.72	122.35	1	5	19	44	2,689
00-17	64	72.56	152.18	1	4	18	81	829
18-24	779	44.35	116.06	1	5	14	36	1,825
25-40	2,559	46.48	109.83	1	6	19	43	2,462
41-64	8,571	50.74	124.36	1	5	18	43	2,689
65+	1,460	60.47	132.21	1	7	24	59	1,992
Alvimopan	0	-	-	-	-	-	-	-
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	0	-	-	-	-	-	-	-
41-64	0	-	-	-	-	-	-	-
65+	0	-	-	-	-	-	-	-
Denosumab	516,921	128.58	136.51	1	27	105	187	2,993
00-17	242	37.87	53.77	5	27	27	34	516
18-24	441	63.22	80.28	1	27	28	55	732
25-40	10,216	61.70	86.14	1	27	30	51	1,998
41-64	268,638	120.00	131.32	1	27	79	185	2,823
65+	237,384	141.37	142.40	1	29	178	188	2,993
Idelalisib	541	15.47	35.91	1	3	5	16	410
00-17	0	-	-	-	-	-	-	-
18-24	0	-	-	-	-	-	-	-
25-40	30	14.67	13.98	1	5	8	24	48
41-64	258	15.10	37.78	1	2	6	15	410
65+	253	15.95	35.83	1	3	5	16	316
Olanzapine Extended Release	217	59.12	134.04	1	3	12	32	777
00-17	7	330.14	258.72	28	75	384	542	681
18-24	74	55.82	124.42	1	3	11	27	662
25-40	47	40.60	72.55	1	3	12	42	350
41-64	79	51.71	139.65	1	4	9	31	777
65+	10	39.50	71.79	1	2	7	48	229
Panobinostat	188	24.67	89.36	1	4	7	15	750
00-17	1	1.00	-	1	1	1	1	1
18-24	0	-	-	-	-	-	-	-
25-40	0	-	-	-	-	-	-	-
41-64	145	24.28	87.66	1	4	7	15	750
65+	42	26.60	97.04	1	4	8	15	635
Romiplostim	54,279	11.90	40.93	1	6	6	9	2,344
00-17	1,224	11.27	32.54	1	6	6	9	650

Table 14c: Descriptive statistics of the length of all gaps between treatment episodes, in days, by age group (years)									
Exposures	Total Gaps	Mean	STD	Min	Q1	Median	Q3	Max	
18-24	1,352	11.26	30.60	1	6	6	10	750	
25-40	5,070	12.31	43.94	1	6	6	11	1,800	
41-64	26,673	12.24	42.98	1	6	6	9	2,344	
65+	19,960	11.42	38.33	1	6	6	9	1,720	
Teduglutide	659	23.53	88.71	1	2	6	17	1,292	
00-17	25	9.04	17.00	1	2	4	7	85	
18-24	15	18.00	25.95	1	4	12	16	106	
25-40	88	22.73	48.98	1	4	6	19	327	
41-64	411	28.03	107.89	1	3	6	19	1,292	
65+	120	12.43	35.62	1	2	5	14	380	
Testosterone undecanoate	12,059	62.19	61.61	1	32	69	71	1,525	
00-17	4	47.25	16.88	32	34	44	61	69	
18-24	70	26.57	24.52	1	13	14	30	109	
25-40	1,631	58.79	58.22	1	29	63	70	1,525	
41-64	8,948	61.43	63.38	1	31	68	71	1,525	
65+	1,406	72.80	53.28	1	62	69	76	846	
Vigabatrin	1,740	20.22	94.91	1	3	5	13	2,315	
00-17	1,516	21.58	100.86	1	3	5	13	2,315	
18-24	111	11.49	42.03	1	2	4	8	438	
25-40	91	11.14	19.24	1	3	5	10	139	
41-64	22	7.68	9.27	1	2	5	10	41	
65+	0	-	-	-	-	-	-	-	

Table 15: Counts of reason for censoring, all episodes and first episode										
	Total		Disenrollment		Evidence of death		DP/Query end date		Episode end	
	N	%	N	%	N	%	N	%	N	%
Exposures										
Alosetron	18,694	100.0	1,082	5.8	0	0.0	214	1.1	18,694	100.0
Alvimopan	7	100.0	0	0.0	0	0.0	0	0.0	7	100.0
Denosumab	673,916	100.0	14,272	2.1	32	0.0	4,760	0.7	673,885	100.0
Idelalisib	859	100.0	73	8.5	5	0.6	7	0.8	854	99.4
Olanzapine Extended Release	938	100.0	3	0.3	0	0.0	0	0.0	938	100.0
Panobinostat	343	100.0	21	6.1	0	0.0	2	0.6	343	100.0
Romiplostim	56,749	100.0	93	0.2	2	0.0	33	0.1	56,747	100.0
Teduglutide	864	100.0	81	9.4	0	0.0	30	3.5	864	100.0
Testosterone undecanoate	14,673	100.0	218	1.5	1	0.0	97	0.7	14,672	100.0
Vigabatrin	2,335	100.0	264	11.3	3	0.1	78	3.3	2,332	99.9
Patients' First Episode										
Alosetron	5,261	100.0	287	5.5	0	0.0	53	1.0	5,261	100.0
Alvimopan	7	100.0	0	0.0	0	0.0	0	0.0	7	100.0
Denosumab	156,995	100.0	4,302	2.7	13	0.0	977	0.6	156,982	100.0
Idelalisib	318	100.0	32	10.1	4	1.3	3	0.9	314	98.7
Olanzapine Extended Release	721	100.0	1	0.1	0	0.0	0	0.0	721	100.0
Panobinostat	155	100.0	7	4.5	0	0.0	0	0.0	155	100.0
Romiplostim	2,470	100.0	15	0.6	1	0.0	6	0.2	2,469	100.0
Teduglutide	205	100.0	20	9.8	0	0.0	4	2.0	205	100.0
Testosterone undecanoate	2,614	100.0	43	1.6	0	0.0	17	0.7	2,614	100.0
Vigabatrin	595	100.0	89	15.0	2	0.3	25	4.2	593	99.7

Table 16: Cohort Attrition Table	
Attrition Criteria	Members
Alosetron	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	7,834 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	7,834 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	7,834 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	7,834 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	5,261 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	5,261 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	5,261 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	5,261 (0.0%)
Alvimopan	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	10 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	10 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	10 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	10 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	7 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	7 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	7 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	7 (0.0%)
Denosumab	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)

Table 16: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	176,215 (0.1%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	176,215 (0.1%)
Exclusion - Members must have at least one episode defining index claim during the query period	176,215 (0.1%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	176,215 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	156,995 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	156,995 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	156,995 (0.1%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	156,995 (0.1%)
Idelalisib	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	357 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	357 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	357 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	357 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	318 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	318 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	318 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	318 (0.0%)
Olanzapine Extended Release	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	846 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	846 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	846 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	846 (0.0%)

Table 16: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	721 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	721 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	721 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	721 (0.0%)
Panobinostat	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	177 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	177 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	177 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	177 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	155 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	155 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	155 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	155 (0.0%)
Romiplostim	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	3,352 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	3,352 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	3,352 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	3,352 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	2,470 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	2,470 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	2,470 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	2,470 (0.0%)
Teduglutide	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)

Table 16: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	250 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	250 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	250 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	250 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	205 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	205 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	205 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	205 (0.0%)
Testosterone undecanoate	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	3,235 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	3,235 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	3,235 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	3,235 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	2,614 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	2,614 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	2,614 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	2,614 (0.0%)
Vigabatrin	
Initial Member Count - Members with a non-missing birth date/sex at any enrollment episode overlapping the query period	149,170,000 (100.0%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N during the query period	120,360,000 (80.7%)
Exclusion - Members must be excluded if they only have enrollment episodes with DrugCov=Y and MedCov=N and DrugCov=N and MedCov=Y or A during the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the age range condition within the query period	120,360,000 (80.7%)
Exclusion - Members must meet chart availability criterion within the query period	120,360,000 (80.7%)
Exclusion - Members must satisfy the demographic (sex, race and hispanic) condition	120,360,000 (80.7%)

Table 16: Cohort Attrition Table	
Attrition Criteria	Members
Exclusion - Members must have at least one claim with cohort-identifying codes within the query period	1,327 (0.0%)
Exclusion - Members must have at least one cohort episode beginning within the age range condition	1,327 (0.0%)
Exclusion - Members must have at least one episode defining index claim during the query period	1,327 (0.0%)
Exclusion - Members must have at least one cohort episode incident with respect to other criteria	1,327 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the pre-index enrollment criterion	595 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the exclusion conditions	595 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the inclusion conditions	595 (0.0%)
Exclusion - Members must have at least one cohort episode satisfying the post-index enrollment criterion	595 (0.0%)

Appendix A. Dates of Available Data for Each Data Partner (DP) up to Request End Date (09/30/2020) as of Query Distribution Date

Data Partner (Masked)	Start Date	End Date
DP01	01/01/2010	09/30/2020

Appendix B. Specifications Used to Define Parameters in this Query

Global Values

Enrollment Criteria: **Medical and Drug Coverage**

Enrollment Gap (Days): **45**

Age Groups (Years): **00-17, 18-24, 25-40, 41-64, 65+**

Reporting Output: **All tables**

Query Period: **01/01/2010-09/30/2020**

Baseline Characteristics Table: **Yes**

Baseline Evaluation Window (Day): **-183,0**

#	Cohort Name	Index Exposure	Pre-Index Enrollment Period (Days)	Washout Period (Days)	Treatment Episode Gap (Days)	Treatment Episode Extension (Days)	Inclusion/Exclusion	Criteria	Criteria Definition	Evaluation Period Start (Day)	Evaluation Period End (Day)
1	Alvimopan	Alvimopan ^[1]	183	183	0	0	--	--	--	--	--
2	Testosterone undecanoate	Testosterone undecanoate ^[2]	183	183	0	0	--	--	--	--	--
3	Panobinostat	Panobinostat ^[3]	183	183	0	0	--	--	--	--	--
4	Teduglutide	Teduglutide ^[4]	183	183	0	0	--	--	--	--	--
5	Alosetron	Alosetron ^[5]	183	183	0	0	--	--	--	--	--
6	Denosumab	Denosumab ^[6]	183	183	0	0	--	--	--	--	--
7	Vigabatrin	Vigabatrin ^[7]	183	183	0	0	--	--	--	--	--
8	Idelalisib	Idelalisib ^[8]	183	183	0	0	--	--	--	--	--
9	Romiplostim	Romiplostim ^[9]	183	183	0	0	--	--	--	--	--
10	Olanzapine ER	olanzapine extended release ^[10]	183	183	0	0	--	--	--	--	--

ICD-9, ICD-10, HCPCS AND CPT are provided by Optum360
NDCs are checked against First Data Bank's MedKnowledge.

Appendix of Generic Names and Chronic Conditions

[1] See Appendix C

[2] See Appendices C and D

[3] See Appendix C

[4] See Appendix C

[5] See Appendix C

[6] See Appendices C and D

[7] See Appendix C

[8] See Appendix C

[9] See Appendices C and D

[10] See Appendices C and D

Baseline Characteristics Table

Acquired Hypothyroidism	Chronic Kidney Disease	Hypertension
Acute Myocardial Infarction	Chronic Obstructive Pulmonary Disease	Ischemic Heart Disease
Alzheimer's Disease	Colorectal Cancer	Lung Cancer
Alzheimer's Disease, Related Disorders, or Senile Dementia	Depression	Osteoporosis
Anemia	Diabetes	Prostate Cancer
Asthma	Endometrial Cancer	Rheumatoid Arthritis / Osteoarthritis
Atrial Fibrillation	Glaucoma	Stroke / Transient Ischemic Attack
Benign Prostatic Hyperplasia	Heart Failure	
Breast Cancer	Hip / Pelvic Fracture	
Cataracts	Hyperlipidemia	

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module

Age Groups - Age groups of members included in the cohort. Strata also used for reporting purposes.

Ambulatory Visit (AV) - A care setting value including visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Baseline Characteristics Table - Optional table containing general characteristics of study population, including background rates of 27 chronic conditions from the CMS Chronic Condition Warehouse (see above if table requested). Users define an evaluation period for the presence of baseline characteristics.

Care Setting - Type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Charlson/Elixhauser Combined Comorbidity Score - Calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Cohort Definition - Cohort includes all valid exposure episodes during the query period. Only the first valid episode's incidence is assessed using the washout period.

Emergency Department (ED) - A care setting value including ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Enrollment Criteria - Type of coverage required during enrollment period. By default, all patients must have medical and drug coverage.

Enrollment Gap - Allowed gap between coverage periods.

Episodes - Treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Inclusion/Exclusion - Contains the comprehensive set of codes used to define additional cohort inclusion and/or exclusion criteria (e.g., restrict cohort to individuals with evidence of a pre-existing condition 183 days before the index date). Criteria could be defined with complex algorithms (e.g., diagnosis codes and drug codes) defined under Criteria Definition.

Inpatient Hospital Stay (IP) - A care setting value including all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - A care setting value including hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - A care setting value including other non-overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - Diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - The period of time which patients can contribute index-defining exposure/events. Data prior to the start date may be used to determine enrollment, washout, and other cohort inclusion criteria.

Treatment Episode Extension - The episode extension adds the selected number of days to the end of an episode to count as exposed time.

Treatment Episode Gap - The maximum number of days allowed between two dispensings to consider them part of the same episode.

Washout Period - The period before an exposure episode during which an individual cannot have evidence of incidence-defining criteria.

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Exposures of Interest in this Request

Generic Name	Brand Name
	Alvimopan
alvimopan	
	Testosterone undecanoate
testosterone undecanoate	
	Panobinostat
panobinostat	
	Teduglutide
teduglutide	
	Alosetron
alosectron HCL	
	Denosumab
denosumab	Prolia 60 mg/mL
	Vigabatrin
vigabatrin	
	Idelalisib
idelalisib	
	Romiplostim
romiplostim injection, powder, lyophilized, for solution	
	Olanzapine Extended Release
olanzapine extended release	ZYPREXA RELPREVV single-use convenience kit

Appendix D. List of Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures of Interest in this Request

Code	Code Category	Code Type	Description
Testosterone undecanoate			
C9023	Procedure	HCPCS	INJECTION, TESTOSTERONE UNDECANOATE, 1 MG
J3145	Procedure	HCPCS	INJECTION, TESTOSTERONE UNDECANOATE, 1 MG
Denosumab			
C9272	Procedure	HCPCS	INJECTION, DENOSUMAB, 1 MG
J0897	Procedure	HCPCS	INJECTION, DENOSUMAB, 1 MG
Romiplostim			
C9245	Procedure	HCPCS	INJECTION, ROMIPLOSTIM, 10 MCG
J2796	Procedure	HCPCS	INJECTION, ROMIPLOSTIM, 10 MICROGRAMS
Olanzapine Extended Release			
J2358	Procedure	HCPCS	INJECTION, OLANZAPINE, LONG-ACTING, 1 MGList